WO2005009943A2 - Substituted tetracycline compounds - Google Patents
Substituted tetracycline compounds Download PDFInfo
- Publication number
- WO2005009943A2 WO2005009943A2 PCT/US2004/020249 US2004020249W WO2005009943A2 WO 2005009943 A2 WO2005009943 A2 WO 2005009943A2 US 2004020249 W US2004020249 W US 2004020249W WO 2005009943 A2 WO2005009943 A2 WO 2005009943A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- hydrogen
- alkenyl
- alkynyl
- aryl
- Prior art date
Links
- 0 C*(C)[C@@](C(CC1Cc(c2c(cc3)O)c3C#C*)[C@]3(*)C(O)=C1C2=O)C(O)=C(C(N)=O)C3=O Chemical compound C*(C)[C@@](C(CC1Cc(c2c(cc3)O)c3C#C*)[C@]3(*)C(O)=C1C2=O)C(O)=C(C(N)=O)C3=O 0.000 description 7
- PTERRNGGGFGWDL-INVFMYNMSA-N CN(C)[C@@H]([C@@H]1C[C@@H]2Cc(c3c(c(C#CCN(C)Cc4ccccc4)c4)O)c4N(C)C)C(O)=C(C(N)=O)C4=[O][C@]14C(O)=C2C3=O Chemical compound CN(C)[C@@H]([C@@H]1C[C@@H]2Cc(c3c(c(C#CCN(C)Cc4ccccc4)c4)O)c4N(C)C)C(O)=C(C(N)=O)C4=[O][C@]14C(O)=C2C3=O PTERRNGGGFGWDL-INVFMYNMSA-N 0.000 description 1
- QMQPTSZZFIKGRR-LINDEHRRSA-N C[C@H](C([C@@H](C([C@@H]1N(C)C)[C@@]23[O]=C2C(C(N)=O)=C1O)O)C(C(c1c(c(CN(CC2)CCC2(F)F)c2)O)=O)=C3O)c1c2N(C)C Chemical compound C[C@H](C([C@@H](C([C@@H]1N(C)C)[C@@]23[O]=C2C(C(N)=O)=C1O)O)C(C(c1c(c(CN(CC2)CCC2(F)F)c2)O)=O)=C3O)c1c2N(C)C QMQPTSZZFIKGRR-LINDEHRRSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
- C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/54—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
- C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
- C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
- C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.
Description
SUBSTITUTED TETRACYCLINE COMPOUNDS
Related Applications This patent application claims priority to U.S. Provisional Patent Application Serial No. 60/530,123, filed December 16, 2003; U.S. Provisional Patent Application Serial No. 60/525,287, filed November 25, 2003; and U.S. Provisional Patent Application Serial No. 60/486,017, filed July 9, 2003, all of which are entitled "Substituted Tetracycline Compounds." The entire contents of each of the aforementioned applications are hereby incorporated herein by reference.
Background of the Invention The development of the tetracycline antibiotics was the direct result of a systematic screening of soil specimens collected from many parts of the world for evidence of microorganisms capable of producing bacteriocidal and/or bacteriostatic compositions. The first of these novel compounds was introduced in 1948 under the name chlortetracycline. Two years later, oxytetracycline became available. The elucidation of the chemical structure of these compounds confirmed their similarity and furnished the analytical basis for the production of a third member of this group in 1952, tetracycline. A new family of tetracycline compounds, without the ring-attached methyl group present in earlier tetracyclines, was prepared in 1957 and became publicly available in 1967; and minocycline was in use by 1972. Recently, research efforts have focused on developing new tetracycline antibiotic compositions effective under varying therapeutic conditions and routes of administration. New tetracycline analogues have also been investigated which may prove to be equal to or more effective than the originally introduced tetracycline compounds. Examples include U.S. Patent Nos. 2,980,584; 2,990,331; 3,062,717; 3,165,531; 3,454,697; 3,557,280; 3,674,859; 3,957,980; 4,018,889; 4,024,272; and 4,126,680. These patents are representative of the range of pharmaceutically active tetracycline and tetracycline analogue compositions. Historically, soon after their initial development and introduction, the tetracyclines were found to be highly effective pharmacologically against rickettsiae; a number of gram-positive and gram-negative bacteria; and the agents responsible for lymphogranuloma venereum, inclusion conjunctivitis, and psittacosis. Hence, tetracyclines became known as "broad spectrum" antibiotics. With the subsequent establishment of their in vitro antimicrobial activity, effectiveness in experimental infections, and pharmacological properties, the tetracyclines as a class rapidly became widely used for therapeutic purposes. However, this widespread use of tetracyclines for both major and minor illnesses and diseases led directly to the emergence of resistance
to these antibiotics even among highly susceptible bacterial species both commensal and pathogenic (e.g., pneumococci and Salmonella). The rise of tetracycline-resistant organisms has resulted in a general decline in use of tetracyclines and tetracycline analogue compositions as antibiotics of choice.
Summary of the Invention: ~ In one embodiment, the invention pertains to a 7,9-substituted tetracycline compound of Formula I:
In another embodiment, the invention pertains to 8-substituted tetracycline compound of formula IN:
wherein: X is CHC(R13Y'Y), CR6'RD, S, NR6, or O; R2, R4 , R4 , R7' and R7 are each hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocychc, heteroaromatic or a prodrug moiety; R4 is NR4 R4 , alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen; R2', R3, R10, R11 and R12 are each hydrogen or a pro-drug moiety; R5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy; R6 and R6 are independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; R7 is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocychc, thionitroso, or-(CH2)0.3 (NR7c)0-1C(=W')WR7a; R8 is an aminomethyl substituted phenyl or substituted pyridinyl; R9 is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocychc, thionitroso, or-(CH2)0-3NR9cC(=Z')ZR9a; R7a, Rn, R7c, R7d, R7e, R7f, R9a, R9b, R9c, R9d, R9e, and R8f are each independently absent, hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocychc, heteroaromatic or a prodrug moiety; W is CR7dR7e, S, O or NR715; W is O, NR7f, or S; Z is CR9dR9e, S, O or NR9b; Z' is O, NR9f, or S; R13 is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl,
alkylamino, or an arylalkyl, and pharmaceutically acceptable salts, esters and prodrugs thereof. In one embodiment, a 13-substituted tetracycline compound is of formula V:
In another further embodiment, the invention pertains, at least in part, to methods for treating subjects for tetracycline responsive states by administering to them an
effective amount of a tetracycline compound of the invention, e.g., a compound of formula I, II, III, IV, N, or a tetracycline compound otherwise described herein.
Detailed Description of the Invention: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. The term "tetracycline compound" includes many compounds with a similar ring structure to tetracycline. Examples of tetracycline compounds include: chlortetracycline, oxytetracycline, demeclocycline, methacycline, sancycline, chelocardin, rolitetracycline, lymecycline, apicycline; clomocycline, guamecycline, meglucycline, mepylcycline, penimepicycline, pipacycline, etamocycline, penimocycline, etc. Other derivatives and analogues comprising a similar four ring structure are also included (See Rogalski, "Chemical Modifications of Tetracyclines," the entire contents of which are hereby incorporated herein by reference). Table 1 depicts tetracycline and several known other tetracycline derivatives.
Table 1
1. 7,9-Substituted Tetracycline Compounds The invention also pertains, at least in part to 7,9-substituted tetracycline compounds. The term "7,9-substituted tetracycline compounds" includes tetracycline compounds with substitution at the 7 and 9- positions. In one embodiment, the substitution at the 7- and 9- positions enhances the ability of the tetracycline compound to perform its intended function, e.g., treat tetracycline responsive states. In an embodiment, the 7,9-substituted tetracycline compound is 7,9-substituted tetracycline (e.g., wherein R4 is NR4 R4"; R4' and R4" are methyl, R5 is hydrogen and X is CR6R6', wherein R6 is methyl and R6 is hydroxy); 7,9-substituted doxycycline (e.g., wherein R4 is NR4 R4"; R4' and R4" are methyl, R5 is hydroxyl and X is CR6R6', wherein R6 is methyl and R6 is hydrogen); or 7, 9- substituted sancycline (wherein R4 is NR4 R4 ; R4 and R4 are methyl; R5 is hydrogen and X is CR6R6 wherein R6 and R6 are hydrogen atoms. In an embodiment, the substitution at the 7 position of the 7, 9-substituted tetracycline compound is not chlorine or trimethylamino. In one embodiment, R4 is hydrogen. In one embodiment, the invention pertains to 7,9-substituted tetracycline compounds of Formula I:
wherein: X is CHC(R13Y'Y), CR6'R6, S, NR6, or O; R2, R2 , R4 , and R4 are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocychc, heteroaromatic or a prodrug moiety; R4 is NR4 R4 , alkyl, alkenyl, alkynyl, hydroxyl, halogen, or hydrogen; R2 , R3, R10, R11 and R12 are each hydrogen or a pro-drug moiety; R5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy; R6 and R6 are each independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; R7 is ethyl, perhalogenated alkenyl, substituted pyridinyl, pyrazinyl, furanyl, or pyrazolyl; R8 is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; R9 is -CH2NR9aR9b; R9a and R9 are each independently hydrogen, alkyl, alkenyl or linked to form a heterocycle; R13 is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; and Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl, and pharmaceutically acceptable salts thereof, provided that R7 and R9 are not both unsubstituted phenyl. In a further embodiment, X is CR6R6'; R2, R2', R6, R6', R8, R10, R11, and R12 are each hydrogen; R is NR R ; R and R are lower alkyl; and R is hydroxy or hydrogen, h another further embodiment, R4 and R4 are each methyl and R5 is hydrogen.
In an embodiment, R7 is ethyl and R9a is alkyl and R >9ybo is alkenyl. In another embodiment, R7 is substituted pyrazinyl Examples of possible substituents include halogens, such as fluorine. In another embodiment, R9a is alkyl and R9b is alkenyl. In another further embodiment, R9a and R9b are linked to form a heterocycle. In a fϊirther embodiment, the linked heterocycle is substituted piperidinyl. In a further embodiment, the piperdinyl is substituted with one or more fluorines or halogenated alkyl groups, e.g., at the 2, 3, 4, or 5 position. In another embodiment, the R9 moiety is (4'trifluoromethyl- piperdin-1-yl) methyl, (4', 4'-difluoro-piperdin-l-yl) methyl, or (4'-fluoropiperdin-l-yl) methyl. In another embodiment, R9a is hydrogen and R9b is alkyl. Other examples of compounds include those wherein R7 is furanyl, and R9a is hydrogen or alkyl and R9b is alkenyl, e.g., 1, 2, 2-trifluoroethenyl. In another embodiment, R9a is hydrogen or alkyl and R9b is alkenyl. In another embodiment, R7 is pyrazolyl and R9a is hydrogen or alkyl and R9 is alkenyl or alkyl. In a further embodiment, the invention pertains to tetracycline compounds
2. 9-Substituted Tetracycline Compounds In another embodiment, the invention pertains to 9-substituted tetracycline compounds. The term "9-substituted tetracycline compounds" includes tetracycline compounds with substitution at the 9 position, one embodiment, the substitution at the 9- position enhances the ability of the tetracycline compound to perform its intended function, e.g., treat tetracycline responsive states. In an embodiment, the 9-substituted tetracycline compound is 9-substituted tetracycline (e.g., wherein R4 is NR4 R4 , R4 and R4 are methyl, R5 is hydrogen and X is CR6R6 , wherein R6 is methyl and R6' is hydroxy, and R7 is hydrogen); 9-substituted doxycycline (e.g., wherein R4 is NR4 R4", R4' and R4" are methyl, R5 is hydroxyl and X is CR6R6', wherein R6 is methyl and R6' is hydrogen, and R7 is hydrogen); 9- substituted minocycline (wherein R4 is NR4 R4 , R4' and R4 are methyl; R5 is hydrogen and X is CR6R6' wherein R6 and R6' are hydrogen atoms, and R7 is dimethylamino); 9-substituted 4-dedimethylamino tetracycline compound, wherein X is CR6R6', R4, R5, R6', R6, and R7 are hydrogen; and 9- substituted sancycline (wherein R4 is NR4 R4 , R4 and R4" are methyl; R5 and R7 are hydrogen and X is CR6R6 wherein R6 and R6 are hydrogen atoms). In another embodiment, the invention pertains to tetracycline compounds of formula II:
3. 7-Substituted Tetracycline Compounds In one embodiment, the invention pertains to novel 7-substituted tetracycline compounds. The term "7-substituted tetracycline compounds" includes tetracycline compounds with substitution at the 7 position. In one embodiment, the substitution at the 7- position enhances the ability of the tetracycline compound to perform its intended function, e.g., treat tetracycline responsive states. In an embodiment, the 7-substituted tetracycline compound is 7-substituted tetracycline (e.g., wherein R4 is NR4 R4 , R4 and
R are methyl, R is hydrogen and X is CR 6π R6' , wherein R is methyl and R »6' is hydroxy); 7-substituted doxycycline (e.g., wherein R4 is NR4 R4 , R4 and R4 are methyl, R5 is hydroxyl and X is CR6R6 , wherein R6 is methyl and R6 is hydrogen); 7-substituted tetracycline compound, wherein X is CR6R6 , R4, R5, R6 , and R6 are hydrogen; or 7-
substituted sancycline (wherein R4 is NR4 R4 , R4' and R4 are methyl; R5 is hydrogen and X is CR6R6' wherein R6 and R6' are hydrogen atoms). The invention pertains, at least in part, to 7-substituted tetracycline compound of Formula III:
4. 8-Substituted Tetracycline Compounds The invention also pertains, at least in part to 8-substituted tetracycline compounds. The term "8-substituted tetracycline compounds" includes tetracycline compounds with substitution at the 8- position, i one embodiment, the substitution at the 8- position enhances the ability of the tetracycline compound to perform its intended
function, e.g., treat tetracycline responsive states. In an embodiment, the 8-substituted tetracycline compound is 8-substituted tetracycline (e.g., wherein R4 is NR4 R4"; R4' and R4 are methyl, R5 is hydrogen and X is CR6R6 , wherein R6 is methyl and R6' is hydroxy); 8-substituted doxycycline (e.g., wherein R4 is NR4 R4 ; R4' and R4 are methyl, R is hydroxyl and X is CR , 6 Rτ»6 , wherein R is methyl and R 6' is hydrogen); or 8 substituted sancycline (wherein R4 is NR4 R4 ; R4 and R4" are methyl; R5 is hydrogen and X is CR6R6' wherein R6 and R6' are hydrogen atoms. In an embodiment, the substitution at the 7 position of the 8-substituted tetracycline compound is not chlorine or trimethylamino. In one embodiment, R4 is hydrogen. In one embodiment, the 8-substituted tetracycline compound is of formula IN:
5. 13-Substituted Methacycline Compounds In one embodiment, a 13 -substituted tetracycline compound is of formula V:
wherein: R2, R4 , R4 , R7 and R7 are each hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocychc, heteroaromatic or a prodrug moiety; R4 is NR4 R4 , alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen; R2', R3, R10, R11 and R12 are each hydrogen or a pro-drug moiety; R5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy; R is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocychc, thionitroso, or -(CH2)0.3 (NR7c)0-1C(=W')^VR7a; R is substituted phenyl or substituted pyridinyl; R9 is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocychc, thionitroso, or -(CH2)0-3NR9cC(=Z')ZR9 ; R7a, R7b, R7c, R7d, R7e, R7f, R9a, R9 , R9c, R9d, R9e, and R8f are each independently absent, hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocychc, heteroaromatic or a prodrug moiety; W is CR7dR7e, S, O or NR7"; W' is O, NR7f, or S; R is 4-alkyl substituted phenyl, and pharmaceutically acceptable salts, esters and prodrugs thereof. In a further embodiment, the invention pertains to compounds wherein R2, R2 ,
R ,8δ, τ R.10 , R.1111, and R , 112Z are each hydrogen; R4 is NR 44'r ΕC,4" ; R and ,4" are lower alkyl; and R5 is hydroxy or hydrogen. In a further embodiment, the phenyl R13 group is substituted with an aminomethyl substituent. In another further embodiment, the aminomethyl substituent is dimethylaminomethyl. In another further embodiment, the invention pertains to compounds of the formula:
and pharmaceutically acceptable salts, esters, and prodrugs thereof.
In one embodiment, the tetracycline compounds of the invention do not include those described in U.S.S.N. 09/660,598, 09/823,884, 09/852,908, 10/819,343,
10/820,456, 09/894,805, 09/895,796, 09/895,812, 09/895,797, 09/895,857, 10/097,634, 10/759,484, 10/337,914, 10/636,437, 10/752,378, or 10/740,961. The entire contents of each of these applications are hereby incorporated herein in their entirety.
6. Methods for Synthesizing Tetracycline Compounds of the Invention The tetracycline compounds of this invention can be synthesized using the methods described in the Schemes and/or by other techniques known to those of ordinary skill in the art. The substituted tetracycline compounds of the invention can be synthesized using the methods described in the following schemes and by using art recognized techniques. All novel substituted tetracycline compounds described herein are included
As shown in Scheme 3, tetracycline compounds of the invention, wherein R is a heterocychc (i.e. thiazole) substituted amino group can be synthesized using the above protocol. 7-amino sancycline (3 A) is reacted with Fmoc-isothiocyanate (3B) to produce the protected thiourea (3C). The protected thiourea (3C) is then deprotected yielding the active sancycline thiourea (3D) compound. The sancycline thiourea (3D) is reacted with an -haloketone (3E) to produce a thiazole substituted 7-amino sancycline (3F).
7- alkenyl tetracycline compounds, such as 7-alkynyl sancycline (4A) and 7- alkenyl sancycline (4B), can be hydrogenated to form 7-alkyl substituted tetracycline compounds (e.g., 7-alkyl sancycline, 4C). Scheme 4 depicts the selective hydrogenation of the 7- position double or triple bond, in saturated methanol and hydrochloric acid solution with a palladium/carbon catalyst under pressure, to yield the product.
SCHEME 5
In Scheme 5, a general synthetic scheme for synthesizing 7-position aryl derivatives is shown. A Suzuki coupling of an aryl boronic acid with an iodosancycline compound is shown. An iodo sancycline compound (5B) can be synthesized from sancycline by treating sancycline (5 A) with at least one equivalent N-iodosuccinimide (NIS) under acidic conditions. The reaction is quenched, and the resulting 7-iodo sancycline (5B) can then be purified using standard techniques known in the art. To form the aryl derivative, 7-iodo sancycline (5B) is treated with an aqueous base (e.g., Na2CO3) and an appropriate boronic acid (5C) and under an inert atmosphere. The reaction is catalyzed with a palladium catalyst (e.g., Pd(OAc)2). The product (5D) can be purified by methods known in the art (such as HPLC). Other 7-aryl, alkenyl, and alkynyl tetracycline compounds can be synthesized using similar protocols. The 7-substituted tetracycline compounds of the invention can also be synthesized using Stille cross couplings. Stille cross couplings can be performed using an appropriate tin reagent (e.g., R-SnBu3) and a halogenated tetracycline compound, (e.g., 7-iodosancycline). The tin reagent and the iodosancycline compound can be treated with a palladium catalyst (e.g., Pd(PPh3)2Cl2 or Pd(AsPh3)2Cl2) and, optionally, with an additional copper salt, e.g., Cul. The resulting compound can then be purified using techniques known in the art.
SCHEME 6 The compounds of the invention can also be synthesized using Heck-type cross coupling reactions. As shown in Scheme 6, Heck-type cross-couplings can be performed by suspending a halogenated tetracycline compound (e.g., 7-iodosancycline, 6A) and an appropriate palladium or other transition metal catalyst (e.g., Pd(OAc)2 and Cul) in an appropriate solvent (e.g., degassed acetonitrile). The substrate, a reactive alkene (6B) or alkyne (6D), and triethylamine are then added and the mixture is heated for several hours, before being cooled to room temperature. The resulting 7-substituted alkenyl (6C) or 7-substituted alkynyl (6E) tetracycline compound can then be purified using techniques known in the art.
SCHEME 7
To prepare 7-(2'-Chloro-alkenyl)-tetracycline compounds, the appropriate 7- (alkynyl)-sancycline (7 A) is dissolved in saturated methanol and hydrochloric acid and stirred. The solvent is then removed to yield the product (7B).
SCHEME 8
As depicted in Scheme 8, 5-esters of 9- substituted tetracycline compounds can be formed by dissolving the 9- substituted compounds (8A) in strong acid (e.g. HF, methanesulphonic acid, and trifluoromethanesulfomc acid) and adding the appropriate carboxylic acid to yield the corresponding esters (8B). As shown in Scheme9 below, 7 and 9 aminomethyl tetracyclines may be synthesized using reagents such as hydroxymethyl-carbamic acid benzyl ester.
The term "alkyl" includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. The term alkyl further includes alkyl groups, which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkyl has 6 or fewer carbon atoms in its backbone (e.g., -C.5 for straight chain, C3-C6 for branched chain), and more preferably 4 or fewer. Likewise, preferred cycloalkyls have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term Cι.-C6 includes alkyl groups containing 1 to 6 carbon atoms. Moreover, the term alkyl includes both "unsubstituted alkyls" and "substituted alkyls", the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can
include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Cycloalkyls can be fixrther substituted, e.g., with the substituents described above. An "alkylaryl" or an "arylalkyl" moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)). The term "alkyl" also includes the side chains of natural and unnatural amino acids. The term "aryl" includes groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiaozole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like. Furthermore, the term "aryl" includes multicyclic aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, napthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine. Those aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles", "heterocycles," "heteroaryls" or "heteroaromatics". The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, arylalkyl aminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocychc rings which are not aromatic so as to form a polycycle (e.g., tetralin). The term "alkenyl" includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond.
For example, the term "alkenyl" includes straight-chain alkenyl groups (e.g., ethylenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. The term alkenyl further includes alkenyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkenyl group has 6 or fewer carbon atoms in its backbone (e.g., C2-Cg for straight chain, C3-C6 for branched chain). Likewise, cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term C2-C6 includes alkenyl groups containing 2 to 6 carbon atoms. Moreover, the term alkenyl includes both "unsubstituted alkenyls" and "substituted alkenyls", the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. The term "alkynyl" includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond. For example, the term "alkynyl" includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. The term alkynyl further includes alkynyl groups which include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkynyl group has 6 or fewer carbon atoms in its backbone (e.g., C2-Cβ for straight chain, C3-C6 for branched chain). The term C2-C6 includes alkynyl groups containing 2 to 6 carbon atoms.
Moreover, the term alkynyl includes both "unsubstituted alkynyls" and "substituted alkynyls", the latter of which refers to alkynyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Unless the number of carbons is otherwise specified, "lower alkyl" as used herein means an alkyl group, as defined above, but having from one to five carbon atoms in its backbone structure. "Lower alkenyl" and "lower alkynyl" have chain lengths of, for example, 2-5 carbon atoms. The term "acyl" includes compounds and moieties which contain the acyl radical (CH3CO-) or a carbonyl group. It includes substituted acyl moieties. The term "substituted acyl" includes acyl groups where one or more of the hydrogen atoms are replaced by for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. The term "acylamino" includes moieties wherein an acyl moiety is bonded to an amino group. For example, the term includes alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido groups. The term "aroyl" includes compounds and moieties with an aryl or heteroaromatic moiety bound to a carbonyl group. Examples of aroyl groups include phenylcarboxy, naphthyl carboxy, etc. The terms "alkoxyalkyl", "alkylaminoalkyl" and "thioalkoxyalkyl" include alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms
replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or sulfur atoms. The term "alkoxy" includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently linked to an oxygen atom. Examples of alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy, and pentoxy groups.
Examples of substituted alkoxy groups include halogenated alkoxy groups. The alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moieties. Examples of halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, etc. The term "amine" or "amino" includes compounds where a nitrogen atom is covalently bonded to at least one carbon or heteroatom. The term includes "alkyl amino" which comprises groups and compounds wherein the nitrogen is bound to at least one additional alkyl group. The term "dialkyl amino" includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups. The term "arylamino" and "diarylamino" include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively. The term "alkylarylamino," "alkylaminoaryl" or
"arylaminoalkyl" refers to an amino group which is bound to at least one alkyl group and at least one aryl group. The term "alkaminoalkyl" refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group. The term "amide," "amido" or "aminocarbonyl" includes compounds or moieties which contain a nitrogen atom which is boxmd to the carbon of a carbonyl or a thiocarbonyl group. The term includes "alkaminocarbonyl" or "alkylaminocarbonyl" groups which include alkyl, alkenyl, aryl or alkynyl groups bound to an amino group bound to a carbonyl group. It includes arylaminocarbonyl and arylcarbonylamino groups which include aryl or heteroaryl moieties boxmd to an amino group which is bound to the carbon of a carbonyl or thiocarbonyl group. The terms
"alkylaminocarbonyl," "alkenylaminocarbonyl," "alkynylaminocarbonyl," "arylaminocarbonyl," "alkylcarbonylamino," "alkenylcarbonylamino," "alkynylcarbonylamino," and "arylcarbonylamino" are included in term "amide."
Amides also include urea groups (ammocarbonylamino) and carbamates (oxycarbonylamino) . The term "carbonyl" or "carboxy" includes compounds and moieties which contain a carbon connected with a double bond to an oxygen atom. The carbonyl can be further substituted with any moiety which allows the compox ds of the invention to perform its intended function. For example, carbonyl moieties may be substituted with alkyls, alkenyls, alkynyls, aryls, alkoxy, aminos, etc. Examples of moieties which contain a carbonyl include aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc. The term "thiocarbonyl" or "thiocarboxy" includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom. The term "ether" includes compounds or moieties which contain an oxygen bonded to two different carbon atoms or heteroatoms. For example, the term includes "alkoxyalkyl" which refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to another alkyl group. The term "ester" includes compounds and moieties which contain a carbon or a heteroatom bound to an oxygen atom which is bonded to the carbon of a carbonyl group. The term "ester" includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, etc. The alkyl, alkenyl, or alkynyl groups are as defined above. The term "thioether" includes compounds and moieties which contain a sulfur atom bonded to two different carbon or hetero atoms. Examples of thioethers include, but are not limited to alkthioalkyls, alkthioalkenyls, and alkthioalkynyls. The term "alkthioalkyls" include compounds with an alkyl, alkenyl, or alkynyl group bonded to a sulfur atom which is bonded to an alkyl group. Similarly, the term "alkthioalkenyls" and alkthioalkynyls" refer to compounds or moieties wherein an alkyl, alkenyl, or alkynyl group is bonded to a sulfur atom which is covalently bonded to an alkynyl group. The term "hydroxy" or "hydroxyl" includes groups with an -OH or -O". The term "halogen" includes fluorine, bromine, chlorine, iodine, etc. The term
"perhalogenated" generally refers to a moiety wherein all hydrogens are replaced by halogen atoms. The terms "polycyclyl" or "polycyclic radical" refer to two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy,
alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, alkylaminoacarbonyl, arylalkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkyl carbonyl, alkenylcarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amido, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino
(including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or heteroaromatic moiety. The term "heteroatom" includes atoms of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus. The term "prodrug moiety" includes moieties which can be metabolized in vivo to a hydroxyl group and moieties which may advantageously remain esterified in vivo. Preferably, the prodrugs moieties are metabolized in vivo by esterases or by other mechanisms to hydroxyl groups or other advantageous groups. Examples of prodrugs and their uses are well known in the art (See, e.g., Berge et al. (1977) "Pharmaceutical Salts", J Pharm. Sci. 66:1-19). The prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form or hydroxyl with a suitable esterifying agent. Hydroxyl groups can be converted into esters via treatment with a carboxylic acid. Examples of prodrug moieties include substituted and unsubstituted, branch or unbranched lower alkyl ester moieties, (e.g., propionoic acid esters), lower alkenyl esters, di-lower alkylamino lower-alkyl esters (e.g., dimethylaminoethyl ester), acylamino lower alkyl esters (e.g., acetyloxymethyl ester), acyloxy lower alkyl esters (e.g., pivaloyloxymethyl ester), aryl esters (phenyl ester), aryl-lower alkyl esters (e.g., benzyl ester), substituted (e.g., with methyl, halo, or methoxy substituents) aryl and aryl-lower alkyl esters, amides, lower-alkyl amides, di-lower alkyl amides, and hydroxy amides. Preferred prodrug moieties are propionoic acid esters and acyl esters. It will be noted that the structure of some of the tetracycline compounds of this invention includes asymmetric carbon atoms. It is to be understood accordingly that the isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. Furthermore, the structures and other compounds and moieties discussed in this application also include all tautomers thereof.
7. Methods for Treating Tetracycline Responsive States The invention also pertains to methods for treating a tetracycline responsive states in subjects, by administering to a subject an effective amount of a tetracycline compound of the invention (e.g., a compound of Formula I, π, III, IN, N or otherwise described herein), such that the tetracycline responsive state is treated. The term "treating" includes curing as well as ameliorating at least one symptom of the state, disease or disorder, e.g., the tetracycline compound responsive state. The language "tetracycline compound responsive state" or "tetracycline responsive state" includes states which can be treated, prevented, or otherwise ameliorated by the administration of a tetracycline compound of the invention, e.g., a 3, 10, and/or 12a substituted tetracycline compound. Tetracycline compound responsive states include bacterial, viral, and fungal infections (including those which are resistant to other tetracycline compounds), cancer (e.g., prostate, breast, colon, lung melanoma and lymph cancers and other disorders characheterized by unwanted cellular proliferation, including, but not limited to, those described in U.S. 6,100,248), arthritis, osteoporosis, diabetes, and other states for which tetracycline compounds have been found to be active (see, for example, U.S. Patent Νos. 5,789,395; 5,834,450; 6,277,061 and 5,532,227, each of which is expressly incorporated herein by reference). Compounds of the invention can be used to prevent or control important mammalian and veterinary diseases such as diarrhea, urinary tract infections, infections of skin and skin structure, ear, nose and throat infections, wound infection, mastitis and the like. In addition, methods for treating neoplasms using tetracycline compounds of the invention are also included (van der Bozert et ah, Cancer Res., 48:6686-6690 (1988)). In a further embodiment, the tetracycline responsive state is not a bacterial infection. In another , embodiment, the tetracycline compounds of the invention are essentially non- antibacterial. For example, non-antibacterial tetracycline compounds of the invention may have MIC values greater than about 4 μg/ml (as measured by assays known in the art and/or the assay given in Example 2). Tetracycline compound responsive states also include inflammatory process associated states (IP AS). The term "inflammatory process associated state" includes states in which inflammation or inflammatory factors (e.g., matrix metalloproteinases (MMPs), nitric oxide (NO), TNF, interleukins, plasma proteins, cellular defense systems, cytokines, lipid metabolites, proteases, toxic radicals, adhesion molecules, etc) are involved or are present in an area in aberrant amounts, e.g., in amounts which may be advantageous to alter, e.g., to benefit the subject. The inflammatory process is the response of living tissue to damage. The cause of inflammation maybe due to physical damage, chemical substances, micro-organisms, tissue necrosis, cancer or other agents.
Acute inflammation is short-lasting, lasting only a few days. If it is longer lasting however, then it may be referred to as chronic inflammation. rPAF's include inflammatory disorders. Inflammatory disorders are generally characterized by heat, redness, swelling, pain and loss of function. Examples of causes of inflammatory disorders include, but are not limited to, microbial infections (e.g., bacterial and fungal infections), physical agents (e.g., burns, radiation, and trauma), chemical agents (e.g., toxins and caustic substances), tissue necrosis and various types of immunologic reactions. Examples of inflammatory disorders include, but are not limited to, osteoarthritis, rheumatoid arthritis, acute and chronic infections (bacterial and fungal, including diphtheria and pertussis); acute and chronic bronchitis, sinusitis, and upper respiratory infections, including the common cold; acute and chronic gastroenteritis and colitis; acute and chronic cystitis and urethritis; acute and chronic dermatitis; acute and chronic conjunctivitis; acute and chronic serositis (pericarditis, peritonitis, synovitis, pleuritis and tendinitis); uremic pericarditis; acute and chronic cholecystis; acute and chronic vaginitis; acute and chronic uveitis; drug reactions; insect bites; burns (thermal, chemical, and electrical); and sunburn. Tetracycline compound responsive states also include NO associated states. The term "NO associated state" includes states which involve or are associated with nitric oxide (NO) or inducible nitric oxide synthase (iNOS). NO associated state includes states which are characterized by aberrant amounts of NO and/or iNOS. Preferably, the NO associated state can be treated by administering tetracycline compounds of the invention, e.g., a 3, 10, and/or 12a substituted tetracycline compound. The disorders, diseases and states described in U.S. Patents Nos. 6,231,894; 6,015,804; 5,919,774; and 5,789,395 are also included as NO associated states. The entire contents of each of these patents are hereby incorporated herein by reference. Other examples of NO associated states include, but are not limited to, malaria, senescence, diabetes, vascular stroke, neurodegenerative disorders (Alzheimer's disease & Huntington's disease), cardiac disease ( reperfusion-associated injury following infarction), juvenile diabetes, inflammatory disorders, osteoarthritis, rheumatoid arthritis, acute, recurrent and chronic infections (bacterial, viral and fungal); acute and chronic bronchitis, sinusitis, and respiratory infections, including the common cold; acute and chronic gastroenteritis and colitis; acute and chronic cystitis and urethritis; acute and chronic dermatitis; acute and chronic conjunctivitis; acute and chronic serositis (pericarditis, peritonitis, synovitis, pleuritis and tendonitis); uremic pericarditis; acute and chronic cholecystis; cystic fibrosis, acute and chronic vaginitis; acute and chronic uveitis; drug reactions; insect bites; burns (thermal, chemical, and electrical); and sunburn.
The term "inflammatory process associated state" also includes, in one embodiment, matrix metalloproteinase associated states (MMP AS). MMP AS include states charachterized by abberrant amounts of MMPs or MMP activity. These are also include as tetracycline compound responsive states which may be treated using compounds of the invention, e.g., 3, 10, and/or 12a substituted tetracycline compoxmds. Examples of matrix metalloproteinase associated states ("MMPAS's") include, but are not limited to, arteriosclerosis, corneal ulceration, emphysema, osteoarthritis, multiple sclerosis(Liedtke et al, Ann. Neurol. 1998, 44:35-46; Chandler et al, J. Neuroimmunol.1997, 72:155-71), osteosarcoma, osteomyelitis, bronchiectasis, chronic pulmonary obstructive disease, skin and eye diseases, periodontitis, osteoporosis, rheumatoid arthritis, ulcerative colitis, inflammatory disorders, tumor growth and invasion (Stetler-Stevenson et al, Annu. Rev. Cell Biol. 1993, 9:541-73; Tryggvason et al, Biochim. Biophys. Ada 1987, 907:191-217; Li et al, Mol. Carcinog. 1998, 22:84- 89)),metastasis, acute lung injury, stroke, ischemia, diabetes, aortic or vascular aneurysms, skin tissue wounds, dry eye, bone and cartilage degradation (Greenwald et al, Bone 1998, 22:33-38; Ryan et α/., Curr. Op. Rheumatol 1996, 8;238-247). Other MMPAS include those described in U.S. Pat. Nos. 5,459,135; 5,321,017; 5,308,839; 5,258,371; 4,935,412; 4,704,383, 4,666,897, and RE 34,656, incorporated herein by reference in their entirety. In another embodiment, the tetracycline compound responsive state is cancer.
Examples of cancers which the tetracycline compounds of the invention maybe useful to treat include all solid tumors, i.e., carcinomas e.g., adenocarcinomas, and sarcomas. Adenocarcinomas are carcinomas derived from glandular tissue or in which the tumor cells form recognizable glandular structures. Sarcomas broadly include tumors whose cells are embedded in a fibrillar or homogeneous substance like embryonic connective tissue. Examples of carcinomas which may be treated using the methods of the invention include, but are not limited to, carcinomas of the prostate, breast, ovary, testis, lung, colon, and breast. The methods of the invention are not limited to the treatment of these tumor types, but extend to any solid tumor derived from any organ system. Examples of treatable cancers include, but are not limited to, colon cancer, bladder cancer, breast cancer, melanoma, ovarian carcinoma, prostatic carcinoma, lung cancer, and a variety of other cancers as well. The methods of the invention also cause the inhibition of cancer growth in adenocarcinomas, such as, for example, those of the prostate, breast, kidney, ovary, testes, and colon. In an embodiment, the tetracycline responsive state of the invention is cancer.
The invention pertains to a method for treating a subject suffering or at risk of suffering from cancer, by administering an effective amount of a substituted tetracycline compound, such that inhibition cancer cell growth occurs, i.e., cellular proliferation,
invasiveness, metastasis, or tumor incidence is decreased, slowed, or stopped. The inhibition may result from inhibition of an inflammatory process, down-regulation of an inflammatory process, some other mechanism, or a combination of mechanisms. Alternatively, the tetracycline compounds may be useful for preventing cancer recurrence, for example, to treat residual cancer following surgical resection or radiation therapy. The tetracycline compounds useful according to the invention are especially advantageous as they are substantially non-toxic compared to other cancer treatments. In a further embodiment, the compounds of the invention are administered in combination with standard cancer therapy, such as, but not limited to, chemotherapy. , Examples of tetracycline responsive states also include neurological disorders which include both neuropsychiatric and neurodegenerative disorders, but are not limited to, such as Alzheimer's disease, dementias related to Alzheimer's disease (such as Pick's disease), Parkinson's and other Lewy diffuse body diseases, senile dementia, Huntington's disease, Gilles de la Tourette's syndrome, multiple sclerosis, amylotrophic lateral sclerosis (ALS), progressive supranuclear palsy, epilepsy, and Creutzfeldt- Jakob disease; autonomic function disorders such as hypertension and sleep disorders, and neuropsychiatric disorders, such as depression, schizophrenia, schizoaffective disorder, Korsakoff s psychosis, mania, anxiety disorders, or phobic disorders; learning or memory disorders, e.g., amnesia or age-related memory loss, attention deficit disorder, dysthymic disorder, major depressive disorder, mania, obsessive-compulsive disorder, psychoactive substance use disorders, anxiety, phobias, panic disorder, as well as bipolar affective disorder, e.g., severe bipolar affective (mood) disorder (BP-1), bipolar affective neurological disorders, e.g., migraine and obesity. Further neurological disorders include, for example, those listed in the American Psychiatric Association's Diagnostic and Statistical manual of Mental Disorders (DSM), the most current version of which is incorporated herein by reference in its entirety. Other examples of tetracycline compound responsive states are described in WO 03/005971A2, U.S.S.N. 60/421,248, and U.S.S.N. 60/480,482, each incorporated herein by reference. The language "in combination with" another therapeutic agent or treatment includes co-administration of the tetracycline compound, (e.g., inhibitor) and with the other therapeutic agent or treatment, administration of the tetracycline compound first, followed by the other therapeutic agent or treatment and administration of the other therapeutic agent or treatment first, followed by the tetracycline compound. The other therapeutic agent may be any agent which is known in the art to treat, prevent, or reduce the symptoms of an IP AS. Furthermore, the other therapeutic agent may be any agent of benefit to the patient when administered in combination with the administration of an tetracycline compound. In one embodiment, the cancers treated by methods of the
invention include those described in U.S. Patent Nos. 6,100,248; 5,843,925; 5,837,696; or 5,668,122, incorporated herein by reference in their entirety. In another embodiment, the tetracycline compound responsive state is diabetes, e.g., juvenile diabetes, diabetes mellitus, diabetes type I, or diabetes type II. In a further embodiment, protein glycosylation is not affected by the administration of the tetracycline compounds of the invention. In another embodiment, the tetracycline compound of the invention is administered in combination with standard diabetic therapies, such as, but not limited to insulin therapy. In a further embodiment, the IP AS includes disorders described in U.S. Patents Nos. 5,929,055; and 5,532,227, incorporated herein by reference in their entirety. In another embodiment, the tetracycline compound responsive state is a bone mass disorder. Bone mass disorders include disorders where a subjects bones are disorders and states where the formation, repair or remodeling of bone is advantageous. For examples bone mass disorders include osteoporosis (e.g., a decrease in bone strength and density), bone fractures, bone formation associated with surgical procedures (e.g., facial reconstruction), osteogenesis imperfecta (brittle bone disease), hypophosphatasia, Paget's disease, fibrous dysplasia, osteopetrosis, myeloma bone disease, and the depletion of calcium in bone, such as that which is related to primary hyperparathyroidism. Bone mass disorders include all states in which the formation, repair or remodeling of bone is advantageous to the subject as well as all other disorders associated with the bones or skeletal system of a subject which can be treated with the tetracycline compounds of the invention. In a further embodiment, the bone mass disorders include those described in U.S. Patents Nos. 5,459,135; 5,231,017; 5,998,390; 5,770,588; RE 34,656; 5,308,839; 4,925,833; 3,304,227; and 4,666,897, each of which is hereby incorporated herein by reference in its entirety. In another embodiment, the tetracycline compound responsive state is acute lung injury. Acute lung injuries include adult respiratory distress syndrome (ARDS), post- pump syndrome (PPS), and trauma. Trauma includes any injury to living tissue caused by an extrinsic agent or event. Examples of trauma include, but are not limited to, crush injuries, contact with a hard surface, or cutting or other damage to the lungs. The invention also pertains to a method for treating acute lung injury by administering a substituted tetracycline compound of the invention. The tetracycline responsive states of the invention also include chronic lung disorders. The invention pertains to methods for treating chronic lung disorders by administering a tetracycline compoxmd, such as those described herein. The method includes administering to a subject an effective amount of a substituted tetracycline compound such that the chronic lung disorder is treated. Examples of chronic lung disorders include, but are not limited, to asthma, cystic fibrosis, and emphesema. In a
further embodiment, the tetracycline compounds of the invention used to treat acute and/or chronic lung disorders such as those described in U.S. Patents No. 5,977,091; 6,043,231; 5,523,297; and 5,773,430, each of which is hereby incorporated herein by reference in its entirety. In yet another embodiment, the tetracycline compound responsive state is ischemia, stroke, or ischemic stroke. The invention also pertains to a method for treating ischemia, stroke, or ischemic stroke by administering an effective amount of a substituted tetracycline compound of the invention, i a further embodiment, the tetracycline compounds of the invention are used to treat such disorders as described in U.S. Patents No. 6,231,894; 5,773,430; 5,919,775 or 5,789,395, incorporated herein by reference. In another embodiment, the tetracycline compound responsive state is a skin wound. The invention also pertains, at least in part, to a method for improving the healing response of the epithelialized tissue (e.g., skin, mucusae) to acute traumatic injury (e.g., cut, burn, scrape, etc.). The method may include using a tetracycline compound of the invention (which may or may not have antibacterial activity) to improve the capacity of the epithelialized tissue to heal acute wounds. The method may increase the rate of collagen accumulation of the healing tissue. The method may also decrease the proteolytic activity in the epthithelialized tissue by decreasing the coUagenolytic and/or gellatinolytic activity of MMPs. In a fiirther embodiment, the tetracycline compound of the invention is administered to the surface of the skin (e.g., topically), ha a further embodiment, the tetracycline compound of the invention used to treat a skin wound, and other such disorders as described in, for example, U.S. Patent Nos. 5,827,840; 4,704,383; 4,935,412; 5,258,371; 5,308,8391 5,459,135; 5,532,227; and 6,015,804; each of which is incorporated herein by reference in its entirety. In yet another embodiment, the tetracycline compound responsive state is an aortic or vascular aneurysm in vascular tissue of a subject (e.g., a subject having or at risk of having an aortic or vascular aneurysm, etc.). The tetracycline compound may by effective to reduce the size of the vascular aneurysm or it may be administered to the subject prior to the onset of the vascular aneurysm such that the aneurysm is prevented. In one embodiment, the vascular tissue is an artery, e.g., the aorta, e.g., the abdominal aorta. In a further embodiment, the tetracycline compounds of the invention are used to treat disorders described in U.S. Patent Nos. 6,043,225 and 5,834,449, incorporated herein by reference in their entirety. Bacterial infections may be caused by a wide variety of gram positive and gram negative bacteria. The compounds of the invention are useful as antibiotics against organisms which are resistant to other tetracycline compounds. The antibiotic activity of the tetracycline compounds of the invention maybe determined using the method
discussed in Example 2, or by using the in vitro standard broth dilution method described in Waitz, J.A., National Commission for Clinical Laboratory Standards, Document M7-A2, vol. 10, no. 8, pp. 13-20, 2nd edition, Nillanova, PA (1990). The tetracycline compounds may also be used to treat infections traditionally treated with tetracycline compounds such as, for example, rickettsiae; a number of gram- positive and gram-negative bacteria; and the agents responsible for lymphogranuloma venereum, inclusion conjunctivitis, psittacosis. The tetracycline compounds may be used to treat infections of, e.g., K. pneumoniae, Salmonella, E. hirae, A. baumanii, B. catarrhalis, H. influenzae, P. aeruginosa, E. faecium, E. coli, S. aureus or E. faecalis. In one embodiment, the tetracycline compound is used to treat a bacterial infection that is resistant to other tetracycline antibiotic compounds. The tetracycline compound of the invention may be administered with a pharmaceutically acceptable carrier. The language "effective amount" of the compound is that amount necessary or sufficient to treat or prevent a tetracycline compound responsive state. The effective amount can vary depending on such factors as the size and weight of the subject, the type of illness, or the particular tetracycline compound. For example, the choice of the tetracycline compound can affect what constitutes an "effective amount". One of ordinary skill in the art would be able to study the aforementioned factors and make the determination regarding the effective amount of the tetracycline compound without undue experimentation. The invention also pertains to methods of treatment against microorganism infections and associated diseases. The methods include administration of an effective amount of one or more tetracycline compoxmds to a subject. The subject can be either a plant or, advantageously, an animal, e.g., a mammal, e.g., a human. In the therapeutic methods of the invention, one or more tetracycline compounds of the invention may be administered alone to a subject, or more typically a compound of the invention will be administered as part of a pharmaceutical composition in mixture with conventional excipient, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral, oral or other desired administration and which do not deleteriously react with the active compounds and are not deleterious to the recipient thereof.
8. Pharmaceutical Compositions of the Invention The invention also pertains to pharmaceutical compositions comprising a therapeutically effective amount of a tetracycline compound (e.g., a compound of Formula I, II, III, IV, N or any other compound described herein) and, optionally, a pharmaceutically acceptable carrier.
The language "pharmaceutically acceptable carrier" includes substances capable of being coadministered with the tetracycline compound(s), and which allow both to perform their intended function, e.g., treat or prevent a tetracycline responsive state. Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohol, vegetable oils, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, etc. The pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously react with the active compoxmds of the invention. The tetracycline compounds of the invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of the tetracycline compounds of the invention that are basic in nature are those that form non- toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and palmoate [i.e., 1,1 - methylene-bis-(2-hydroxy-3-naphthoate)] salts. Although such salts must be pharmaceutically acceptable for administration to a subject, e.g., a mammal, it is often desirable in practice to initially isolate a tetracycline compound of the invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The preparation of other tetracycline compounds of the invention not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art. The preparation of other tetracycline compounds of the invention not specifically described in the foregoing experimental section can be accomplished using
combinations of the reactions described above that will be apparent to those skilled in the art. The tetracycline compounds of the invention that are acidic in nature are capable of forming a wide variety of base salts. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those tetracycline compounds of the invention that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmaceutically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines. The pharmaceutically acceptable base addition salts of tetracycline compounds of the invention that are acidic in nature may be formed with pharmaceutically acceptable cations by conventional methods. Thus, these salts may be readily prepared by treating the tetracycline compound of the invention with an aqueous solution of the desired pharmaceutically acceptable cation and evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, a lower alkyl alcohol solution of the tetracycline compound of the invention may be mixed with an alkoxide of the desired metal and the solution subsequently evaporated to dryness. The preparation of other tetracycline compounds of the invention not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art. The tetracycline compounds of the invention and pharmaceutically acceptable salts thereof can be administered via either the oral, parenteral or topical routes. In general, these compounds are most desirably administered in effective dosages, depending upon the weight and condition of the subject being treated and the particular route of administration chosen. Variations may occur depending upon the species of the subject being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. The pharmaceutical compositions of the invention may be administered alone or in combination with other known compositions for treating tetracycline responsive states in a subject, e.g., a mammal. Preferred mammals include pets (e.g., cats, dogs, ferrets, etc.), farm animals (cows, sheep, pigs, horses, goats, etc.), lab animals (rats, mice, monkeys, etc.), and primates (chimpanzees, humans, gorillas). The language "in combination with" a known composition is intended to include simultaneous administration of the composition of the invention and the known composition,
administration of the composition of the invention first, followed by the known composition and administration of the known composition first, followed by the composition of the invention. -Any of the therapeutically composition known in the art for treating tetracycline responsive states can be used in the methods of the invention. The tetracycline compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any of the routes previously mentioned, and the administration may be carried out in single or multiple doses. For example, the novel therapeutic agents of this invention can be administered advantageously in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays (e.g., aerosols, etc.), creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the therapeutically-effective compoxmds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight. For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof. The compositions of the invention may be formulated such that the tetracycline compositions are released over a period of time after administration. For parenteral administration (including intraperitoneal, subcutaneous, intravenous, intradermal or intramuscular injection), solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily
solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. For parenteral application, examples of suitable preparations include solutions, preferably oily or aqueous solutions as well as suspensions, emulsions, or implants, including suppositories. Therapeutic compounds may be formulated in sterile form in multiple or single dose formats such as being dispersed in a fluid carrier such as sterile physiological saline or 5% saline dextrose solutions commonly used with injectables. Additionally, it is also possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin. Examples of methods of topical administration include transdermal, buccal or sublingual application. For topical applications, therapeutic compounds can be suitably admixed in a pharmacologically inert topical carrier such as a gel, an ointment, a lotion or a cream. Such topical carriers include water, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, or mineral oils. Other possible topical carriers are liquid petrolatum, isopropylpalmitate, polyethylene glycol, ethanol 95%, polyoxyethylene monolauriate 5% in water, sodium lauryl sulfate 5% in water, and the like, i addition, materials such as anti-oxidants, humectants, viscosity stabilizers and the like also may be added if desired. For enteral application, particularly suitable are tablets, dragees or capsules having talc and/or carbohydrate carrier binder or the like, the carrier preferably being lactose and/or corn starch and/or potato starch. A syrup, elixir or the like can be used wherein a sweetened vehicle is employed. Sustained release compositions can be formulated including those wherein the active component is protected with differentially degradable coatings, e.g., by microencapsulation, multiple coatings, etc. In addition to treatment of human subjects, the therapeutic methods of the invention also will have significant veterinary applications, e.g. for treatment of livestock such as cattle, sheep, goats, cows, swine and the like; poultry such as chickens, ducks, geese, turkeys and the like; horses; and pets such as dogs and cats. Also, the compounds of the invention may be used to treat non-animal subjects, such as plants. It will be appreciated that the actual preferred amounts of active compounds used in a given therapy will vary according to the specific compound being utilized, the particular compositions formulated, the mode of application, the particular site of administration, etc. Optimal administration rates for a given protocol of administration can be readily ascertained by those skilled in the art using conventional dosage determination tests conducted with regard to the foregoing guidelines. In general, compounds of the invention for treatment can be administered to a subject in dosages used in prior tetracycline therapies. See, for example, the Physicians'
Desk Reference. For example, a suitable effective dose of one or more compounds of the invention will be in the range of from 0.01 to 100 milligrams per kilogram of body weight of recipient per day, preferably in the range of from 0.1 to 50 milligrams per kilogram body weight of recipient per day, more preferably in the range of 1 to 20 milligrams per kilogram body weight of recipient per day. The desired dose is suitably administered once daily, or several sub-doses, e.g. 2 to 5 sub-doses, are administered at appropriate intervals through the day, or other appropriate schedule. It will also be understood that normal, conventionally known precautions will be taken regarding the administration of tetracyclines generally to ensure their efficacy under normal use circumstances. Especially when employed for therapeutic treatment of humans and animals in vivo, the practitioner should take all sensible precautions to avoid conventionally known contradictions and toxic effects. Thus, the conventionally recognized adverse reactions of gastrointestinal distress and inflammations, the renal toxicity, hypersensitivity reactions, changes in blood, and impairment of absorption through aluminum, calcium, and magnesium ions should be duly considered in the conventional manner. Furthermore, the invention also pertains to the use of a tetracycline compound of formula I, If, III, IN, N, or any other compound described herein, for the preparation of a medicament. The medicament may include a pharmaceutically acceptable carrier and the tetracycline compound is an effective amount, e.g., an effective amount to treat a tetracycline responsive state.
EXEMPLIFICATION OF THE INVENTION
Example 1: Synthesis of Selected Compounds of the Invention
7-Ethyl-9-( ', 4,-Difluoro-N-Piperidinyl methvD-Sancycline
7-(TrifluoroalkenyT)-9-(2'- trans-2-methyl-2-butene aminomethyl Sancycline
7-(2 ' -P yrazinvD-9-(3 ' ,3 ' , 3 ' -Trifluoro-propylaminoVmethyl-Sancvcline
Step 1: 7-Iodo-9-aminomethyl sancycline (569 mg, 1 mmol), indium trichloride (22 mg, 0.1 mmol) and trifluoropropionaldehyde (224 μL, 2 mmol) were taken in DMF (25 mL) and stirred at room temperature for 10 minutes. To this solution, sodium triacetoxyborohydride (635 mg, 3 mmol) was added at once and the reaction mixture was stirred at room temperature for another 30 minutes. Progress of the reaction was monitored by HPLC and LC/MS. Reaction was completed in 30 minutes. DMF was then removed and the crude material obtained was then precipitated using diethyl ether/ MeOH (100/10 mL). Filteration of the precipitate gave a yellow powder, which was used for the next step without further purification.
Step 2: 7-Iodo-9- (3,3,3-trifluoro-propylamino)-methyl-sancycline (665 mg, 1 mmol), Pd(PPh3)4 (115mg, 0.1 mmol), Pd(OAc)2 (22 mg, 0.1 mmol), Cul (19 mg, 0.1 mmol) were taken in anhydrous DMF (30 mL) and purged with argon for 5 minutes. To this solution, 2-pyrazine-stannane (738 mg, 2 mmol) was added and the reaction mixture was stirred at room temperature for 2 hours. Reaction was completed by then (monitored by HPLC/LCMS). It was then filtered through celite, washed with 5 mL of methanol. Solvent was evaporated to dryness. The crude material obtained was purified using preparative HPLC. A yellow solid was obtained after evaporating the fractions, which was converted to its HC1 salt using MeOH/HCl solution. LC-MS (M+l 618).
7-Amino-9-Iodo-Doxycycline
To 500 mg of 9-iodo-doxycycline in 10 ml of methanesulfonic acid was added 1.1 eq. of sodium nitrate. The reaction mixture was left stirring for several hrs and was monitored by analytical HPLC. The intermediate (9-Iodo-7-nitro-doxycycline) was isolated by diluting he solution with ice-water, adjusting the pH with sodium hydroxide (pH ~4) and extracting the product with n-butanol. The solvent was evaporated under reduced pressure and the crude material was subjected to hydrogenation using 10% Pd/C in methanol. The final product was obtained via preparative HPLC. The LCMS showed the desired material; MS: 586. The structure was confirmed by NMR.
7-(Dimethylamino)-9-(4 ' A ' -DifluoropiperdinyD-Doxycycline
To a solution of 105 mg (0.16 mmol) of 9-(4-difluoropiperdinyl)-doxycycline dihydrochloride in 10 mL of methanesulfonic acid at room temperature, was added 19.4 mg (0.19 mmol) of potassium nitrate dissolved in 4 mL of methanesulfonic acid. The
reaction was monitored by LCMS. After 30 minutes, the reaction mixture was poured over ice and diluted to 160 mL with ice water. The solution was loaded onto a 2.5 x 1 cm column of divinylbenzene resin (1000 angstrom, 5-25 μm) equilibrated with water. The crude reaction mixture was washed with excess water to remove methanesulfonic acid followed an excess of IN ammonium acetate to neutralize the crude mixture. The excess ammonium acetate was removed by a water wash and the crude compound was purified by elution with 40% methanol in water with 0.1% HC1. The purified material was evaporated to dryness to yield 70 mg of 9-(4-difluoropiperdinyl)-7-nitro- doxycycline as the dihydrochloride salt (Yield = 63%). LCMS (MH+) 623. To 70 mg (0.10 mmol) of 9-(4-difluoropiperdinyl)-7-nitro-doxycycline dihydrochloride in 20 mL of methoxyethanol was added 200 mL of sulfuric acid and 162 mL (2 mmol) of 37% formaldehyde in water. The reaction mixture was purged with Argon gas and 40 mg of 10% wet Palladium on carbon was added with stirring. The reaction was hydrogenated at room temperature and 760 torr hydrogen gas for 12 hours. The crude reaction was passed through Celite and evaporated to dryness. The crude reaction mixture was purified by preparative HPLC (1 inch x 25 cm, Phenomenex Luna C18, 10 mm, Gradient 5-40% B buffer, A = water + 0.1% TFA, B = acetonitrile + 0.1% TFA, detection at 280 nm) to yield 20 mg of the product as the dihydrochloride salt (Yield = 30%). LCMS (MH+) 621.
7-Diethylamino-9-(4' -Fluoro-N-Piperidinyl methvD-Sancycline
Acetaldehyde (5.2mL, 9.32mmol) was added to reaction solution and contents were stirred at room temperature xmder argon for 20 minutes. Pd/C (1.25g) was added to reaction and contents were evacuated/flushed with argon 3 times. A balloon filled with
H2 was placed on top neck of reaction flask and reaction solution was evacuated/flushed with H2 three times. The reaction was stirred overnight under H pressure at room temperature. The reaction was monitored by HPLC and LC/MS and shown to be complete by morning. The mixture was filtered through celite and solvent evaporated in vacuo. The residue was redissolved in water (IL) and the pH was adjusted with Et3N to pH~5. The mixture was filtered again through celite and loaded onto a DVB column.
The compoxmd eluted at 15% CH3CN. Clean fractions were evaporated and dried overnight under vacuum. A yellow/brown solid (7-diethylamino sancycline) was isolated in 40% yield. 7-diethylamino sancycline (1.4g, 2.88mmol)was dissolved in TFA Triflic acid (22mL/6mL) in a lOOmL flask. N-iodosuccinimide (1.2g, 5.78mmol) was added portionwise to reaction solution every 20 minutes. The reaction monitored by HPLC and LC/MS and shown to be complete within 3 hours. The reaction solution was diluted with H2O (0.1% TFA) (30mL) and the solvent was evaporated. The residue was redissolved in H2O (lOOmL) and loaded onto a 5g DNB cartridge. The crude product eluted at 30-50% CH3CΝ. A yellow/brown crude product was isolated in 90% yield. This crude material, 7-diethylamino-9-iodo-sancycline, (1.8g, 2.95mmol) was dissolved in anhydrous DMF (lOOmL) in a 2 neck IL round bottom flask and placed under argon. NaOAc (0.61g, 7.36mmol) was added to reaction solution and stirred at room temperature 45min. Pd(PPh3)4 (1.02g, 8.85mmol) was added to reaction and a CO-filled balloon was placed on top neck of reaction flask. CO was bubbled through reaction solution for lOmin. then flask opened to CO balloon. SnBu3H (0.8g, 2.95mmol) was added via syringe pump to reaction solution over 1 hour while heating to 65°C (oil bath temperature). The reaction was monitored by LC/MS and shown to be complete upon addition of tin hydride. H2O (0.1% TFA, 0.3L) was added to the reaction flask and a precipitate formed. The mixture was filtered through celite and the filtrate was evaporated in vacuo. A brown solid in 90% yield (crude material) was isolated. 7-diethylamino-9-formyl-sancycline (0.25g, 0.49mmol) was dissolved in DMF (lOmL). InCl3 (O.Olg, 0.049mmol), 4-fluoroρiρeridine.HCl (0.15g, 0.98mmol), and Et3N (0.09g, 0.98mmol) were added to reaction solution. The reaction was stirred at room temperature xmder argon 45 minutes. NaCNBH3 (0.043g, 0.68mmol) was added to the reaction and it was monitored by HPLC and LC/MS. The reaction was shown to be complete in 3 hours and it was quenched with MeOH (30mL). The final product was isolated by preparative HPLC in 10% yield as a yellow solid. ESI-MS: m/z (M + H) 601.
Synthesis of 7- Aminomethyl Doxycycline
9-(4'-Difluoromethylene-N-piperidinyl methyl Minocycline
Synthesis of 9-(4'-Fluoro-N-PiperdinvD methyl Doxycycline
Synthesis of 9-(Benzyl-methyl-amino)-Propynyl -Minocycline
Step 2: Hydrobromic acid (30% in acetic acid) (14 mL) was added to a flask and cooled to 0 C. 9-Azido-sancycline (lg, 2.2 mmol) was added to the flask and the reaction was left to stir for one hour. After 1 hour, the reaction was complete. The reaction mixture was precipitated in 300 mL of diethyl ether. After letting the solution settle, the top layer of diethyl ether was decanted and the reaction mixture was dried xmder vaccum. A brown-black solid was then dissolved in methanol and precipitated using diethyl ether. The solid obtained was filtered and dried under vaccum.
Step 3: To a stirred solution (cooled at 0 C, ice-bath) of 8-bromo-9-amino-sancycline (828 mg , 1.6 mmol) in 200 mL of MeOH, 48% HBF4 solution (0.53 mL, 4.0 mmol) was added slowly under an argon atmosphere. After 5 minutes, n-BuNO2 (0.2 mL, 1.79 mmol ) was added slowly (dropwise). The reaction mixture was then stitrred at 0 C for 2 hours and left overnight at room temperature (monitored by HPLC/LC-MS). The solvent was evaporated and the crude material obtained was precipitated using diethyl ether (300 mL). The solid obtained was filtered and dried under vaccum.
Step 4: 8-Bromo-sancycline (492 mg, 1 mmol) and Pd(OAc)2 (22 mg, 0.1 mmol) were taken in methanol (150 mL) and purged with argon while heating the reaction mixture at 65 C (oil bath temperature). After 10 minutes, an aqueous solution of sodium carbonate (315 mg, 3 mmol in 10 mL of water) was added. A yellow precipitate was obtained which was further heated for another 10 minutes, before adding a DMF solution of the boronic acid( 300 mg, 2 mmol in 10 mL of DMF). The reaction was then heated at 65 C for 3 hours. The reaction was monitored by HPLC/LCMS. The mixture was cooled down to room temperature and then filtered through celite. The solvent was then evaporated and the crude materialobtained was precipitated using methanol/diethyl ether (10/200 mL). The crude material was then filtered and dried xmder vacuum. The yellow-brown material obtained was used as such without further purification.
Step 5: To a solution of 8-(2-formyl-phenyl)-sancycline (518 mg, 1 mmol) in 30 mL of DCE under an argon atmosphere, 2-fluoro-ethylamine hydrochloride (198 mg, 2 mmol) and triethylamine (202 μL, 2 mmol) were added. The reaction mixture was then stirred at room temperature for 2 hours. The reaction was monitored by using HPLC/LCMS, and was completed in 2 hours. The solvent was then evaporated and the crude material was purified using preparative HPLC to afford the desired compound. LC-MS (M+l 566).
7-Pyrazolyl-Sancycline
Synthesis of9-r(2,2,2-Trifluoro-ethyl -hvdrazonomethyl]-Minocvcline
HPLC/LCMS, and was completed in 30 minutes. The solvent was then evaporated and the crude material was purified using preparative HPLC to afford the desired compoxmd. LC-MS (M+l 582).
Synthesis of 9-(l '-Isopropyl-4 '-piperidinyl) amino Sancycline
Synthesis of 9-(3-t-butyl-N-imidazolyl)-methylVMinocvcline
Synthesis of 9-(2-thiol 5-methyl-N-imidazolyl -methyl Minocycline
Synthesis of 7-(2' ,2 '-dimethyl-prop vDamino methyl Sancycline
Synthesis of 9-(Benzoimidazolyr)-Minocycline
Example 2: In vitro Minimum Inhibitory Concentration (MIC) Assay The following assay is used to determine the efficacy of the tetracycline compounds against common bacteria. 2 mg of each compound is dissolved in 100 μl of DMSO. The solution is then added to cation-adjusted Mueller Hinton broth (CAMHB), which results in a final compound concentration of 200 μg per ml. The tetracycline compound solutions are diluted to 50 μL volumes, with a test compound concentration of .098 μg/ml. Optical density (OD) determinations are made from fresh log-phase broth cultures of the test strains. Dilutions are made to achieve a final cell density of 1x10 CFU/ml. At OD=l, cell densities for different genera should be approximately:
E. coli lxl 09 CFU/ml S. aureus 5xl08 CFU/ml
Enterococcus sp. 2r 5x 109 CFU/ml
50 μl of the cell suspensions are added to each well of microtiter plates. The final cell density should be approximately 5x105 CFU/ml. These plates are
incubated at 35°C in an ambient air incubator for approximately 18 hr. The plates are read with a microplate reader and are visually inspected when necessary. The MIC is defined as the lowest concentration of the tetracycline compound that inhibits growth.
EQUIVALENTS Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of the present invention and are covered by the following claims. The contents of all references, patents, and patent applications cited throughout this application are hereby incorporated by reference. The appropriate components, processes, and methods of those patents, applications and other documents may be selected for the present invention and embodiments thereof.
Claims
A substituted tetracycline compound of Formula I:
2. The tetracycline compound of claim 1 , wherein X is CR6R6' ; R2, R2', R6, R6', R8, R10, R11, and R12 are each hydrogen; R4 is NR4R4"; R4' and R4" are lower alkyl; and R5 is hydroxy or hydrogen.
3. The tetracycline compound of claim 2, wherein R4 and R4 are each methyl and R5 is hydrogen.
4. The tetracycline compound of any one of claims 1-3, wherein R7 is ethyl and R9a is alkyl and R is alkenyl.
5. The tetracycline compound of any one of claims 1-3, wherein R7 is substituted pyrazinyl.
6. The tetracycline compound of claim 5, wherein R7 is substituted with a fluorine.
7. The tetracycline compound of claim 5 or 6, wherein R9a is alkyl and R9 is alkenyl.
8. The tetracycline compound of claim 5 or 6, wherein R9a and R9b are linked to form a heterocycle.
9. The tetracycline compound of claim 5 or 6, wherein R9a is hydrogen and R9b is alkyl.
10. The tetracycline compound of anyone of claims 1-3, wherein R7 is furanyl, and R9a is hydrogen or alkyl and R9b is alkenyl.
11. The tetracycline compound of any one of claims 1 -3, wherein R7 is 1 , 2, 2- trifluoroethenyl.
12. The tetracyline compound of claim 11, wherein R9a is hydrogen or alkyl and R9b is alkenyl.
13. The tetracycline compound of any one of claims 1-3, wherein R7 is pyrazolyl and R9a is hydrogen or alkyl and R9b is alkenyl or alkyl.
14. A tetracycline compound selected from the group consisting of:
and pharmaceutically acceptable salts, esters, and prodrugs thereof.
15. A tetracycline compound of formula II:
wherein: X is CHC(R13Y'Y), CR6'R6, S, NR6, or O; R2, R4', R4", R7' and R7" are each hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocychc, heteroaromatic or a prodrug moiety; R4 is NR4 R4 , alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen; R2 , R3, R10, R11 and R12 are each hydrogen or a pro-drug moiety; R5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy; R and R are independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; R7 is NR7 R7 , alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, or hydrogen; o R is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; R9 is -CH2NR9aR9b or linked with R10 to form a furanyl ring; R9a is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic,or heteroaromatic; R is hydrogen or alkyl; R8 is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; R is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl; Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl, and pharmaceutically acceptable salts, esters and prodrugs thereof.
16. The tetracycline compound of claim 15, wherein R4is NR4 R4 ; X is CR6R6 ; R is NR7 R7", R2, R2', R5, R6, R6', R8, R9, R10, R11, and R , 12 are each hydrogen; and, R 4' , R
R7 , and R7 are each lower alkyl.
17. The tetracycline compound of claim 15, wherein R4 is NR R ; X is CR6R6 , is hydrogen, R2, R2', , R7, R6', R8, R9, R10, R11, and R12 are each hydrogen; R5 is hydroxy, and R4', R4 , and R6are each lower alkyl.
18. The tetracycline compound of claim 15, wherein R9a is alkyl, alkenyl, or arylalkyl.
19. The tetracycline compound of claim 18, wherein R9a is alkyl substituted with an alkoxy, alkenyl, heterocychc, cyano, halogen, amido, carbonyl, or hydroxy moiety.
20. The tetracycline compound of claim 18, wherein R9a is substituted or unsubstituted benzyl.
21. The tetracycline compound of claim 18, wherein R9b is hydrogen or substituted or unsubstituted alkyl.
22. The tetracycline compound of claim 15, wherein R9a and R9b are linked to form a pyrrolidinyl, piperazinyl, piperidinyl, pyrazinyl, azapanyl, thiomorpholinyl, morpholinyl, tetrahydroquinolinyl, or decahydroquinolinyl ring.
23. The tetracycline compoxmd of claim 22, wherein said ring is substituted with one or more halogens or halogenated alkyl groups.
24. The tetracycline compound of claim 15, wherein R9 is 4'trifluoromethyl- piperdin-1-yl) methyl, (4', 4'-difluoro-piperdin-l-yl) methyl, or (4'-fluoropiperdin-l-yl) methyl.
26. A tetracycline compound of formula El:
27. The tetracycline compound of claim 26, wherein R4 is NR4R4"; X is
CR6R6', R2, R2', R5, R6, R6', R8, R10, R11, and R12 are each hydrogen; and, R4', and R4 are each methyl.
28. The tetracycline compound of claim 26, wherein R7 is phenyl substituted with -CH2- N(CH3)2, -CH2-. H-CH(CH3)2, -CH2-N(CH3)-CH(CH3)2, -CH2-N- piperdinyl), -CH2 H-CH3, -CH2-NH-cyclopropyl, CH2-NH-t-butyl, -CH2-N(CH3)- benzyl, -CH2-N(CH3)-CH2-CH=CH2, CH2-NH-(CH2)2-CF3, CH2--NH-CH2-C(=O)-NH2, or -CH2-NH-cyclohexyl.
29. The tetracycline compound of claim 28, wherein said phenyl is further substituted with a fluorine, methoxy, or alkyl group.
30. The tetracycline compound of claim 26, wherein R7 is substituted furanyl.
31. The tetracycline compound of claim 30, wherein said furanyl is substituted with an aminoalkyl moiety.
32. The tetracycline compound of claim 26, wherein R7 is substituted or unsustituted thiophenyl.
33. The tetracycline compound of claim 26, wherein R7 is substituted pyridinyl. is:
35. A tetracycline
36. The tetracycline compound of claim 35, wherein X is CR^6'; R2, R2', R6, R6', Rs8, R10, R11 , and R12 are each hydrogen; R4 is NR4 R4"; R4' and R4" are lower alkyl; and R5 is hydroxy or hydrogen.
37. The tetracycline compound of claim 36, wherein said substituted tetracycline
38. A tetracycline compound of the formula N:
39. The tetracycline compound of claim 38, wherein said tetracycline compound is:
40. A method for treating a tetracycline responsive state in a subject, comprising administering to said subject an effective amount of a tetracycline compound of any one of claims 1, 14, 15, 25, 26, 34, 35, or 38, such that said subject is treated.
41. The method of claim 40, wherein said tetracycline responsive state is a bacterial infection, a viral infection, or a parasitic infection.
42. The method of claim 41 , wherein said bacterial infection is associated with E. coli.
43. The method of claim 41 , wherein said bacterial infection is associated with S. aureus.
44. The method of claim 41 , wherein said bacterial infection is associated with E. faecάlis.
45. The method of claim 40, wherein said bacterial infection is resistant to other tetracycline antibiotics.
46. The method of claim 40, wherein said tetracycline associated state is malaria.
47. The method of claim 40, wherein said subject is a human.
48. The method of anyone of claims 40, wherein said tetracycline compound is administered with a pharmaceutically acceptable carrier.
49. A pharmaceutical composition comprising a therapeutically effective amoxmt of a tetracycline compound of any one of claims 1, 14, 15, 25, 26, 34, 35, or 38 and a pharmaceutically acceptable carrier.
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006518680A JP4733028B2 (en) | 2003-07-09 | 2004-06-25 | Substituted tetracycline compounds |
| EA200600221A EA200600221A1 (en) | 2003-07-09 | 2004-06-25 | SUBSTITUTED TETRACYCLINE COMPOUNDS (OPTIONS), PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OF TETRACYCLINE-SENSITIVE CONDITION IN SUBJECT |
| KR1020067000487A KR101228706B1 (en) | 2003-07-09 | 2004-06-25 | Substituted Tetracycline Compounds |
| AU2004259659A AU2004259659B2 (en) | 2003-07-09 | 2004-06-25 | Substituted tetracycline compounds |
| CA002531728A CA2531728A1 (en) | 2003-07-09 | 2004-06-25 | Substituted tetracycline compounds |
| EP04756012A EP1648859B1 (en) | 2003-07-09 | 2004-06-25 | Substituted tetracycline compounds |
| CNA2004800256351A CN1845897A (en) | 2003-07-09 | 2004-06-25 | Substituted tetracycline compounds |
| IL173019A IL173019A0 (en) | 2003-07-09 | 2006-01-08 | Substituted tetracycline compounds |
| IL206939A IL206939A0 (en) | 2003-07-09 | 2010-07-11 | Substituted tetracycline compounds |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48601703P | 2003-07-09 | 2003-07-09 | |
| US60/486,017 | 2003-07-09 | ||
| US52528703P | 2003-11-25 | 2003-11-25 | |
| US60/525,287 | 2003-11-25 | ||
| US53012303P | 2003-12-16 | 2003-12-16 | |
| US60/530,123 | 2003-12-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005009943A2 true WO2005009943A2 (en) | 2005-02-03 |
| WO2005009943A3 WO2005009943A3 (en) | 2005-06-16 |
Family
ID=34108825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2004/020249 WO2005009943A2 (en) | 2003-07-09 | 2004-06-25 | Substituted tetracycline compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20050143352A1 (en) |
| EP (6) | EP2319828A3 (en) |
| JP (2) | JP4733028B2 (en) |
| KR (1) | KR101228706B1 (en) |
| CN (3) | CN1845897A (en) |
| AU (1) | AU2004259659B2 (en) |
| CA (1) | CA2531728A1 (en) |
| EA (3) | EA201100956A1 (en) |
| IL (2) | IL173019A0 (en) |
| WO (1) | WO2005009943A2 (en) |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007014154A2 (en) * | 2005-07-21 | 2007-02-01 | Paratek Pharmaceuticals, Inc. | 10-substituted tetracyclines and methods of use thereof |
| WO2008079363A2 (en) * | 2006-12-21 | 2008-07-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
| WO2009009042A1 (en) * | 2007-07-06 | 2009-01-15 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing substituted tetracycline compounds |
| EP2033950A1 (en) * | 2004-10-25 | 2009-03-11 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| US7534766B2 (en) | 2004-11-05 | 2009-05-19 | Wyeth | Glucuronide metabolites and epimers thereof of tigecycline |
| JP2009524675A (en) * | 2006-01-24 | 2009-07-02 | パラテック ファーマシューティカルズ インコーポレイテッド | Methods to increase the oral bioavailability of tetracycline |
| US7858601B2 (en) | 2004-10-25 | 2010-12-28 | Paratek Pharmaceuticals, Inc. | 4-substituted tetracyclines and methods of use thereof |
| EP2277504A1 (en) * | 2002-10-24 | 2011-01-26 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
| JP2011093914A (en) * | 2006-12-21 | 2011-05-12 | Paratek Pharmaceuticals Inc | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections |
| EP2408192A2 (en) | 2004-04-16 | 2012-01-18 | James A. Aman | Multiple view compositing and object tracking system |
| WO2012068106A2 (en) | 2010-11-15 | 2012-05-24 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| US8440646B1 (en) | 2006-10-11 | 2013-05-14 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of Bacillus anthracis infections |
| US8487093B2 (en) | 2008-01-18 | 2013-07-16 | Merck Sharp & Dohme Corp. | β-lactamase inhibitors |
| EP2738156A1 (en) * | 2011-07-26 | 2014-06-04 | KBP Biosciences Co., Ltd. | 9-aminomethyl substituted tetracycline compound |
| US8796245B2 (en) | 2008-08-08 | 2014-08-05 | Tetraphase Pharmaceuticals, Inc. | C7-fluoro substituted tetracycline compounds |
| US9315451B2 (en) | 2009-05-08 | 2016-04-19 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| US9434680B2 (en) | 2007-04-27 | 2016-09-06 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing and purifying aminoalkyl tetracycline compounds |
| US9573895B2 (en) | 2012-08-31 | 2017-02-21 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| US9624166B2 (en) | 2009-08-28 | 2017-04-18 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| US10961190B2 (en) | 2016-10-19 | 2021-03-30 | Tetraphase Pharmaceuticals, Inc. | Crystalline forms of eravacycline |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6756365B2 (en) * | 1991-11-06 | 2004-06-29 | Trustees Of Tufts College | Reducing tetracycline resistance in living cells |
| CA2318580A1 (en) * | 1998-01-23 | 1999-07-29 | Mark L. Nelson | Pharmaceutically active compounds and methods of use thereof |
| US8106225B2 (en) * | 1999-09-14 | 2012-01-31 | Trustees Of Tufts College | Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| EP2327686A3 (en) * | 1999-09-14 | 2012-08-22 | Trustees Of Tufts College | Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| WO2001052858A1 (en) | 2000-01-24 | 2001-07-26 | Trustees Of Tufts College | Tetracycline compounds for treatment of cryptosporidium parvum related disorders |
| BR0109725A (en) * | 2000-03-31 | 2003-02-04 | Tufts College | Substituted tetracycline compound, method for treating a tetracycline-responsive state in a mammal, pharmaceutical composition, method for synthesizing a 7- or 9-substituted tetracycline compound, and reactive intermediate |
| AU2001259701A1 (en) * | 2000-05-15 | 2001-11-26 | Paratek Pharmaceuticals, Inc | 7-substituted fused ring tetracycline compounds |
| US20040224927A1 (en) * | 2000-06-16 | 2004-11-11 | Trustees Of Tufts College | 7-N-substituted phenyl tetracycline compounds |
| US20020128238A1 (en) * | 2000-06-16 | 2002-09-12 | Nelson Mark L. | 7-phenyl-substituted tetracycline compounds |
| BRPI0112269B8 (en) | 2000-07-07 | 2021-05-25 | Paratek Pharm Innc | 9-aminomethyl substituted minocycline compound, and pharmaceutical composition |
| US7094806B2 (en) | 2000-07-07 | 2006-08-22 | Trustees Of Tufts College | 7, 8 and 9-substituted tetracycline compounds |
| MXPA03000056A (en) * | 2000-07-07 | 2003-07-14 | Tufts College | 7-substituted tetracycline compounds. |
| AU2002250331A1 (en) * | 2001-03-13 | 2002-09-24 | Paratek Pharmaceuticals, Inc. | 7-pyrollyl tetracycline compounds and methods of use thereof |
| US7553828B2 (en) * | 2001-03-13 | 2009-06-30 | Paratek Pharmaceuticals, Inc. | 9-aminomethyl substituted minocycline compounds |
| CA2440757A1 (en) | 2001-03-14 | 2002-09-19 | Michael Draper | Substituted tetracycline compounds as synergistic antifungal agents |
| US8088820B2 (en) * | 2001-04-24 | 2012-01-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
| US20060194773A1 (en) * | 2001-07-13 | 2006-08-31 | Paratek Pharmaceuticals, Inc. | Tetracyline compounds having target therapeutic activities |
| WO2003055441A2 (en) * | 2001-08-02 | 2003-07-10 | Paratek Pharmaceuticals, Inc. | Medicaments |
| EP2311799A1 (en) * | 2002-01-08 | 2011-04-20 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
| CN1649582A (en) * | 2002-03-08 | 2005-08-03 | 帕拉特克药品公司 | Amino-methyl substituted tetracycline compounds |
| WO2003079984A2 (en) | 2002-03-21 | 2003-10-02 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| JP4416652B2 (en) * | 2002-07-12 | 2010-02-17 | パラテック ファーマシューティカルズ インコーポレイテッド | 3, 10 and 12a substituted tetracycline compounds |
| CA2503446C (en) * | 2002-10-24 | 2012-12-18 | Paratek Pharmaceuticals, Inc. | Methods of using substituted tetracycline compounds to modulate rna |
| EP1656341A1 (en) * | 2003-07-09 | 2006-05-17 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
| CN1845897A (en) | 2003-07-09 | 2006-10-11 | 帕拉特克药品公司 | Substituted tetracycline compounds |
| US20060287283A1 (en) * | 2003-07-09 | 2006-12-21 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
| TWI261038B (en) * | 2004-08-11 | 2006-09-01 | Bo-Cheng Chen | Bicycle gear-shifting handgrip |
| CA2597212A1 (en) * | 2005-02-04 | 2006-08-10 | Paratek Pharmaceuticals, Inc. | 11a, 12-derivatives of tetracycline compounds |
| CA2652346A1 (en) | 2006-05-15 | 2007-11-22 | Paratek Pharmaceuticals, Inc. | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds |
| US7935687B2 (en) | 2007-04-12 | 2011-05-03 | Paratek Pharmaceuticals, Inc. | Methods for treating spinal muscular atrophy using tetracycline compounds |
| NZ586445A (en) | 2007-11-29 | 2012-06-29 | Actelion Pharmaceuticals Ltd | Phosphonic acid derivates and their use as p2y12 receptor antagonists |
| JP2011513404A (en) | 2008-03-05 | 2011-04-28 | パラテック ファーマシューティカルズ インコーポレイテッド | Minocycline compounds and methods of use thereof |
| PT2271348T (en) * | 2008-03-28 | 2018-04-16 | Paratek Pharm Innc | Oral tablet formulation of tetracycline compound |
| US20100022483A1 (en) * | 2008-04-14 | 2010-01-28 | Paratek Pharmaceuticals, Inc. | Substituted Tetracycline Compounds |
| WO2010006292A1 (en) * | 2008-07-11 | 2010-01-14 | Neumedics | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits |
| AP2011005631A0 (en) * | 2008-09-19 | 2011-04-30 | Paratek Pharmaceuticals Ind | Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment. |
| BR112019008897A2 (en) | 2016-11-01 | 2019-08-13 | Paratek Pharm Innc | method for treating community-acquired bacterial pneumonia. |
Citations (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2980584A (en) | 1957-10-29 | 1961-04-18 | Pfizer & Co C | Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation |
| US2990331A (en) | 1956-11-23 | 1961-06-27 | Pfizer & Co C | Stable solutions of salts of tetracyclines for parenteral administration |
| US3062717A (en) | 1958-12-11 | 1962-11-06 | Pfizer & Co C | Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation |
| US3165531A (en) | 1962-03-08 | 1965-01-12 | Pfizer & Co C | 13-substituted-6-deoxytetracyclines and process utilizing the same |
| US3304227A (en) | 1965-07-15 | 1967-02-14 | Loyal E Loveless | Antibiotic-containing animal feed |
| US3454697A (en) | 1965-06-08 | 1969-07-08 | American Cyanamid Co | Tetracycline antibiotic compositions for oral use |
| US3557280A (en) | 1966-05-31 | 1971-01-19 | Koninklijke Gist Spiritus | Stable solutions of oxytetracycline suitable for parenteral and peroral administration and process of preparation |
| US3674859A (en) | 1968-06-28 | 1972-07-04 | Pfizer | Aqueous doxycycline compositions |
| US3957980A (en) | 1972-10-26 | 1976-05-18 | Pfizer Inc. | Doxycycline parenteral compositions |
| US4018889A (en) | 1976-01-02 | 1977-04-19 | Pfizer Inc. | Oxytetracycline compositions |
| US4024272A (en) | 1974-09-06 | 1977-05-17 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Tetracyclic compounds |
| US4126680A (en) | 1977-04-27 | 1978-11-21 | Pfizer Inc. | Tetracycline antibiotic compositions |
| US4666897A (en) | 1983-12-29 | 1987-05-19 | Research Foundation Of State University | Inhibition of mammalian collagenolytic enzymes by tetracyclines |
| US4704383A (en) | 1983-12-29 | 1987-11-03 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
| US4925833A (en) | 1983-12-29 | 1990-05-15 | The Research Foundation Of State University Of New York | Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis |
| US4935412A (en) | 1983-12-29 | 1990-06-19 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
| US5231017A (en) | 1991-05-17 | 1993-07-27 | Solvay Enzymes, Inc. | Process for producing ethanol |
| US5258371A (en) | 1992-05-29 | 1993-11-02 | Kuraray Co., Ltd. | Method to reduce connective tissue destruction |
| US5308839A (en) | 1989-12-04 | 1994-05-03 | The Research Foundation Of State University Of New York | Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline |
| US5321017A (en) | 1989-12-04 | 1994-06-14 | The Research Foundation Of State University Of New York | Composition comprising fluriprofen and effectively non-antibacterial tetracycline to reduce bone loss |
| USRE34656E (en) | 1983-12-29 | 1994-07-05 | The Research Foundation Of State University Of New York | Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency |
| US5523297A (en) | 1993-03-02 | 1996-06-04 | The Research Foundation Of State University Of New York | Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines |
| US5532227A (en) | 1992-11-17 | 1996-07-02 | The Research Foundation Of State University Of New York | Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive glycosylation of different types of collagen and other proteins during diabetes |
| US5668122A (en) | 1993-07-28 | 1997-09-16 | Fife; Rose S. | Method to treat cancer with tetracyclines |
| US5770588A (en) | 1991-02-11 | 1998-06-23 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions of the prevention and treatment of root caries |
| US5773430A (en) | 1997-03-13 | 1998-06-30 | Research Foundation Of State University Of New York | Serine proteinase inhibitory activity by hydrophobic tetracycline |
| US5789395A (en) | 1996-08-30 | 1998-08-04 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
| US5827840A (en) | 1996-08-01 | 1998-10-27 | The Research Foundation Of State University Of New York | Promotion of wound healing by chemically-modified tetracyclines |
| US5834449A (en) | 1996-06-13 | 1998-11-10 | The Research Foundation Of State University Of New York | Treatment of aortic and vascular aneurysms with tetracycline compounds |
| US5834450A (en) | 1994-02-17 | 1998-11-10 | Pfizer Inc. | 9- (substituted amino) -alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics |
| US5837696A (en) | 1997-01-15 | 1998-11-17 | The Research Foundation Of State University Of New York | Method of inhibiting cancer growth |
| US5843925A (en) | 1994-12-13 | 1998-12-01 | American Cyanamid Company | Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth |
| US5919774A (en) | 1996-12-10 | 1999-07-06 | Eli Lilly And Company | Pyrroles as sPLA2 inhibitors |
| US5929055A (en) | 1997-06-23 | 1999-07-27 | The Research Foundation Of State University Of New York | Therapeutic method for management of diabetes mellitus |
| US5977091A (en) | 1998-09-21 | 1999-11-02 | The Research Foundation Of State University Of New York | Method of preventing acute lung injury |
| US5998390A (en) | 1998-09-28 | 1999-12-07 | The Research Foundation Of State University Of New York | Combination of bisphosphonate and tetracycline |
| US6015804A (en) | 1998-09-11 | 2000-01-18 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds to enhance interleukin-10 production |
| US6043225A (en) | 1992-06-12 | 2000-03-28 | Board Of Regents Of The University Of Washington | Diagnosis and treatment of arterial chlamydial granuloma |
| US6043231A (en) | 1993-03-02 | 2000-03-28 | The Research Foundation Of State Univ. Of New York | Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines |
| US6231894B1 (en) | 1999-10-21 | 2001-05-15 | Duke University | Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase |
| US6277061B1 (en) | 1998-03-31 | 2001-08-21 | The Research Foundation Of State University Of New York | Method of inhibiting membrane-type matrix metalloproteinase |
| WO2003005971A2 (en) | 2001-07-13 | 2003-01-23 | Paratek Pharmaceuticals, Inc. | Tetracycline compounds having target therapeutic activities |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US604804A (en) | 1898-05-31 | Shuttle for looms | ||
| US459135A (en) | 1891-09-08 | Alonzo french | ||
| USRE26271E (en) | 1967-09-26 | Reductive alkylation process | ||
| US883915A (en) | 1907-10-14 | 1908-04-07 | Elias F Slear | Toy gun. |
| US3007965A (en) | 1959-02-13 | 1961-11-07 | American Cyanamid Co | New tetracyclines produced by streptomyces aureofaciens |
| US3043875A (en) * | 1959-10-22 | 1962-07-10 | Pfizer & Co C | Halogenated tetracycline derivatives and processes for their preparation |
| FR1003M (en) | 1960-03-09 | 1961-12-18 | Erba Carlo Spa | Tetracycline-based antibiotic derivatives. |
| FR1430859A (en) * | 1960-05-23 | 1966-05-25 | ||
| US3338963A (en) * | 1960-10-28 | 1967-08-29 | American Cyanamid Co | Tetracycline compounds |
| US3219671A (en) | 1961-04-14 | 1965-11-23 | American Cyanamid Co | Substituted 6-deoxytetracyclines and 6-demethyl-6-deoxytetracyclines |
| GB955766A (en) | 1961-06-14 | 1964-04-22 | Ciba Ltd | New thioethers and process for their manufacture |
| US3862225A (en) * | 1961-08-18 | 1975-01-21 | Pfizer | D-ring substituted tetracyclines |
| US3069467A (en) | 1961-08-28 | 1962-12-18 | Pfizer & Co C | Hydrolysis of 2-decarboxamido-2-cyano-6-deoxy-tetracycline derivatives |
| GB973376A (en) * | 1961-10-19 | 1964-10-28 | Ajinomoto Kk | A process for producing l-glutamic acid |
| USRE26253E (en) * | 1963-05-17 | 1967-08-15 | And z-alkylamino-g-deoxytetracycline | |
| US3277172A (en) | 1964-07-10 | 1966-10-04 | Squibb & Sons Inc | Tetraphenylboron derivatives of tetracycline antibiotics |
| US3609188A (en) | 1964-10-29 | 1971-09-28 | American Cyanamid Co | 4-dedimethylamino-4-substituted-amino-6-demethyltetracyclines |
| US3345379A (en) | 1965-02-26 | 1967-10-03 | American Cyanamid Co | 7-imidomethyl-6-demethyl-6-deoxytetracyclines |
| US3350557A (en) | 1965-06-09 | 1967-10-31 | Szymanski Ronald | Fog lens attachments for vehicle headlights |
| US3397230A (en) * | 1966-03-14 | 1968-08-13 | American Cyanamid Co | Nitration of tetracyclines |
| US3433834A (en) * | 1966-03-14 | 1969-03-18 | American Cyanamid Co | Nitration of 11a-chloro tetracyclines |
| US3341585A (en) | 1966-05-06 | 1967-09-12 | American Cyanamid Co | Substituted 7-and/or 9-amino-6-deoxytetracyclines |
| US3849493A (en) | 1966-08-01 | 1974-11-19 | Pfizer | D-ring substituted 6-deoxytetracyclines |
| US3345410A (en) | 1966-12-01 | 1967-10-03 | American Cyanamid Co | Substituted 7- and/or 9-amino tetracyclines |
| US3403179A (en) | 1967-01-10 | 1968-09-24 | American Cyanamid Co | Novel 7-(1, 2-bis-substituted-hydrazino)-tetracyclines and methods of preparing same |
| US3483251A (en) | 1967-03-03 | 1969-12-09 | American Cyanamid Co | Reductive alkylation process |
| US3373196A (en) * | 1967-03-21 | 1968-03-12 | American Cyanamid Co | 7-and/or 9-(lower alkyl) amino-5a, 6-anhydrotetracyclines |
| US3360561A (en) | 1967-06-19 | 1967-12-26 | American Cyanamid Co | Nitration of tetracyclines |
| US3518306A (en) * | 1968-02-19 | 1970-06-30 | American Cyanamid Co | 7- and/or 9-(n-nitrosoalkylamino)-6-demethyl-6-deoxytetracyclines |
| US3579579A (en) * | 1968-04-18 | 1971-05-18 | American Cyanamid Co | Substituted 7- and/or 9-amino-6-demethyl-6-deoxytetracyclines |
| US3795707A (en) * | 1970-12-28 | 1974-03-05 | Rachelle Labor Italia Spa | Manufacture of alpha-6-deoxytetracyclines |
| NL158172B (en) | 1972-09-18 | 1978-10-16 | Farmaceutici Italia | PROCESS FOR PREPARING TETRACYCLINE DERIVATIVES WITH A 7-PLACE SUBSTITUENT. |
| DE2418142A1 (en) | 1974-04-13 | 1975-11-06 | Hoechst Ag | TETRACYCLIN DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION |
| DE2527568A1 (en) | 1974-06-25 | 1976-01-15 | Farmaceutici Italia | PROCESS FOR THE PRODUCTION OF ALKYLTE TRACYCLINES AND NEW TETRACYCLIN DERIVATIVES |
| US5064821A (en) | 1982-11-18 | 1991-11-12 | Trustees Of Tufts College | Method and compositions for overcoming tetracycline resistance within living cells |
| US5589470A (en) | 1990-02-26 | 1996-12-31 | Trustees Of Tufts College | Reducing tetracycline resistance in living cells |
| US4806529A (en) * | 1982-11-18 | 1989-02-21 | Trustees Of Tufts College, Tufts University | Tetracycline activity enhancement |
| US4806372A (en) * | 1985-02-15 | 1989-02-21 | Georgia Oil & Gas Co., Inc. | Nitrite-free-curing of bacon and product thereof |
| US5494903A (en) * | 1991-10-04 | 1996-02-27 | American Cyanamid Company | 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
| US5281628A (en) * | 1991-10-04 | 1994-01-25 | American Cyanamid Company | 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines |
| DE69232302T4 (en) | 1991-10-04 | 2003-02-13 | American Cyanamid Co | 7-Substituted-9-substituted amino-6-demethyl-6-deoxy-tetracyclines |
| US6756365B2 (en) * | 1991-11-06 | 2004-06-29 | Trustees Of Tufts College | Reducing tetracycline resistance in living cells |
| US5442059A (en) * | 1992-08-13 | 1995-08-15 | American Cyanamid Company | 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines |
| US5284963A (en) * | 1992-08-13 | 1994-02-08 | American Cyanamid Company | Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines |
| US5420272A (en) | 1992-08-13 | 1995-05-30 | American Cyanamid Company | 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines |
| US5328902A (en) * | 1992-08-13 | 1994-07-12 | American Cyanamid Co. | 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines |
| SG47520A1 (en) * | 1992-08-13 | 1998-04-17 | American Cyanamid Co | New method for the production of 9-amino-6-demethyl-6-deoxytetracycline |
| US5248797A (en) | 1992-08-13 | 1993-09-28 | American Cyanamid Company | Method for the production of 9-amino-6-demethyl-6-deoxytetracycline |
| US5371076A (en) | 1993-04-02 | 1994-12-06 | American Cyanamid Company | 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines |
| US5675030A (en) | 1994-11-16 | 1997-10-07 | American Cyanamid Company | Method for selective extracting a 7-(hydrogen or substituted amino)-9- (substituted glycyl) amido!-6-demethyl-6-deoxytetracycline compound |
| US5567693A (en) | 1994-12-13 | 1996-10-22 | American Cyanamid Company | Method for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth |
| AU693013B2 (en) | 1995-05-03 | 1998-06-18 | Pfizer Inc. | Novel tetracycline derivatives |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| CA2318580A1 (en) | 1998-01-23 | 1999-07-29 | Mark L. Nelson | Pharmaceutically active compounds and methods of use thereof |
| US6506740B1 (en) * | 1998-11-18 | 2003-01-14 | Robert A. Ashley | 4-dedimethylaminotetracycline derivatives |
| US6946453B2 (en) | 1998-11-18 | 2005-09-20 | Collagenex Pharmaceuticals, Inc. | 4-dedimethylaminotracycline derivatives |
| ES2272097T3 (en) | 1998-11-18 | 2007-04-16 | Collagenex Pharmaceuticals, Inc. | NEW DERIVATIVES OF 4-DEDIMETILAMINOTETRACICLINA. |
| US6256365B1 (en) * | 1999-08-16 | 2001-07-03 | Analogic Corporation | Apparatus and method for reconstruction of images in a computed tomography system using oblique slices |
| EP2327686A3 (en) * | 1999-09-14 | 2012-08-22 | Trustees Of Tufts College | Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| US6500812B2 (en) | 1999-09-14 | 2002-12-31 | Paratek Pharmaceuticals, Inc. | 13-substituted methacycline compounds |
| US6849615B2 (en) * | 1999-09-14 | 2005-02-01 | Paratek Pharmaceuticals, Inc. | 13-substituted methacycline compounds |
| US8106225B2 (en) | 1999-09-14 | 2012-01-31 | Trustees Of Tufts College | Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| WO2001052858A1 (en) * | 2000-01-24 | 2001-07-26 | Trustees Of Tufts College | Tetracycline compounds for treatment of cryptosporidium parvum related disorders |
| AU2001243253A1 (en) | 2000-02-24 | 2001-09-03 | Biocryst Pharmaceuticals, Inc. | Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
| BR0109725A (en) | 2000-03-31 | 2003-02-04 | Tufts College | Substituted tetracycline compound, method for treating a tetracycline-responsive state in a mammal, pharmaceutical composition, method for synthesizing a 7- or 9-substituted tetracycline compound, and reactive intermediate |
| AU2001259701A1 (en) | 2000-05-15 | 2001-11-26 | Paratek Pharmaceuticals, Inc | 7-substituted fused ring tetracycline compounds |
| US20020132798A1 (en) * | 2000-06-16 | 2002-09-19 | Nelson Mark L. | 7-phenyl-substituted tetracycline compounds |
| US20040224927A1 (en) * | 2000-06-16 | 2004-11-11 | Trustees Of Tufts College | 7-N-substituted phenyl tetracycline compounds |
| US20020128238A1 (en) | 2000-06-16 | 2002-09-12 | Nelson Mark L. | 7-phenyl-substituted tetracycline compounds |
| US20020128237A1 (en) | 2000-06-16 | 2002-09-12 | Nelson Mark L. | 7-N-substituted phenyl tetracycline compounds |
| US20050143353A1 (en) * | 2000-07-07 | 2005-06-30 | Paratek Pharmaceuticals, Inc. | 13-Substituted methacycline compounds |
| US7094806B2 (en) | 2000-07-07 | 2006-08-22 | Trustees Of Tufts College | 7, 8 and 9-substituted tetracycline compounds |
| MXPA03000056A (en) * | 2000-07-07 | 2003-07-14 | Tufts College | 7-substituted tetracycline compounds. |
| BRPI0112269B8 (en) * | 2000-07-07 | 2021-05-25 | Paratek Pharm Innc | 9-aminomethyl substituted minocycline compound, and pharmaceutical composition |
| EP2166000A1 (en) * | 2000-07-07 | 2010-03-24 | Trustees Of Tufts College | 7-, 8- and 9-substituted tetracycline compounds |
| GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| US7553828B2 (en) * | 2001-03-13 | 2009-06-30 | Paratek Pharmaceuticals, Inc. | 9-aminomethyl substituted minocycline compounds |
| AU2002250331A1 (en) * | 2001-03-13 | 2002-09-24 | Paratek Pharmaceuticals, Inc. | 7-pyrollyl tetracycline compounds and methods of use thereof |
| EP2298732A1 (en) * | 2001-03-13 | 2011-03-23 | Paratek Pharmaceuticals, Inc. | 7,9-Substituted tetracycline compounds |
| EP1241160A1 (en) * | 2001-03-13 | 2002-09-18 | Glaxo Group Limited | Tetracycline derivatives and their use as antibiotic agents |
| CA2440757A1 (en) * | 2001-03-14 | 2002-09-19 | Michael Draper | Substituted tetracycline compounds as synergistic antifungal agents |
| CA2457234A1 (en) * | 2001-03-14 | 2002-09-19 | Mark L. Nelson | Substituted tetracycline compounds as antifungal agents |
| US8088820B2 (en) | 2001-04-24 | 2012-01-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
| ATE455092T1 (en) * | 2001-04-24 | 2010-01-15 | Paratek Pharm Innc | SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA |
| US20060194773A1 (en) | 2001-07-13 | 2006-08-31 | Paratek Pharmaceuticals, Inc. | Tetracyline compounds having target therapeutic activities |
| WO2003055441A2 (en) * | 2001-08-02 | 2003-07-10 | Paratek Pharmaceuticals, Inc. | Medicaments |
| US20030069721A1 (en) * | 2001-09-10 | 2003-04-10 | Paratek Pharmaceuticals, Inc. | Computational method for determining oral bioavailability |
| CN1564690A (en) | 2001-10-05 | 2005-01-12 | 泰特拉吉尼克斯医药公司 | Tetracycline derivatives and methods of use thereof |
| EP2311799A1 (en) * | 2002-01-08 | 2011-04-20 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
| CN1649582A (en) * | 2002-03-08 | 2005-08-03 | 帕拉特克药品公司 | Amino-methyl substituted tetracycline compounds |
| WO2003079984A2 (en) * | 2002-03-21 | 2003-10-02 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| JP4416652B2 (en) | 2002-07-12 | 2010-02-17 | パラテック ファーマシューティカルズ インコーポレイテッド | 3, 10 and 12a substituted tetracycline compounds |
| CA2503446C (en) * | 2002-10-24 | 2012-12-18 | Paratek Pharmaceuticals, Inc. | Methods of using substituted tetracycline compounds to modulate rna |
| CA2502464A1 (en) * | 2002-10-24 | 2004-05-06 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
| EP1656341A1 (en) * | 2003-07-09 | 2006-05-17 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
| CN1845897A (en) | 2003-07-09 | 2006-10-11 | 帕拉特克药品公司 | Substituted tetracycline compounds |
| US20060287283A1 (en) | 2003-07-09 | 2006-12-21 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
| JP5010284B2 (en) * | 2004-01-15 | 2012-08-29 | パラテック ファーマシューティカルズ インコーポレイテッド | Aromatic A-ring derivatives of tetracycline compounds |
| WO2005082860A1 (en) | 2004-02-27 | 2005-09-09 | National Research Council Of Canada | Tetracyclines and their use as calpain inhibitors |
| CN103214409B (en) | 2004-05-21 | 2015-10-21 | 哈佛大学校长及研究员协会 | The synthesis of tsiklomitsin and analogue thereof |
| WO2006047671A2 (en) * | 2004-10-25 | 2006-05-04 | Paratek Pharmaceuticals, Inc. | 4-aminotetracyclines and methods of use thereof |
| EP2284164A3 (en) * | 2004-10-25 | 2011-09-21 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| CA2597212A1 (en) | 2005-02-04 | 2006-08-10 | Paratek Pharmaceuticals, Inc. | 11a, 12-derivatives of tetracycline compounds |
| WO2007014154A2 (en) * | 2005-07-21 | 2007-02-01 | Paratek Pharmaceuticals, Inc. | 10-substituted tetracyclines and methods of use thereof |
| AU2007208214B2 (en) * | 2006-01-24 | 2013-02-14 | Paratek Pharmaceuticals, Inc. | Methods of increasing oral bioavailability of tetracyclines |
| CA2652346A1 (en) * | 2006-05-15 | 2007-11-22 | Paratek Pharmaceuticals, Inc. | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds |
| ES2701725T3 (en) | 2006-12-21 | 2019-02-25 | Paratek Pharm Innc | Compounds of substituted tetracycline for the treatment of inflammatory skin disorders |
| US7935687B2 (en) * | 2007-04-12 | 2011-05-03 | Paratek Pharmaceuticals, Inc. | Methods for treating spinal muscular atrophy using tetracycline compounds |
| EP2213655A1 (en) | 2007-04-27 | 2010-08-04 | Paratek Pharmaceuticals, Inc. | Methods For Purifying Aminoalkyl Tetracycline Compounds |
| EA201070048A1 (en) * | 2007-07-06 | 2010-10-29 | Паратек Фармасьютикалс, Инк. | METHODS OF SYNTHESIS OF SUBSTITUTED COMPOUNDS OF TETRACYCLINE (OPTIONS) |
| US9763401B2 (en) | 2012-11-13 | 2017-09-19 | Phytogen Seed Company Llc | Cotton variety PX8262RF |
| US9763402B1 (en) | 2014-03-04 | 2017-09-19 | Pioneer Hi-Bred International, Inc. | Soybean variety XBP48012 |
-
2004
- 2004-06-25 CN CNA2004800256351A patent/CN1845897A/en active Pending
- 2004-06-25 EA EA201100956A patent/EA201100956A1/en unknown
- 2004-06-25 KR KR1020067000487A patent/KR101228706B1/en not_active IP Right Cessation
- 2004-06-25 EP EP10184700A patent/EP2319828A3/en not_active Withdrawn
- 2004-06-25 WO PCT/US2004/020249 patent/WO2005009943A2/en active Application Filing
- 2004-06-25 AU AU2004259659A patent/AU2004259659B2/en not_active Ceased
- 2004-06-25 EP EP10184570A patent/EP2295404A3/en not_active Withdrawn
- 2004-06-25 EA EA201001081A patent/EA201001081A1/en unknown
- 2004-06-25 CN CN201010142413A patent/CN101786991A/en active Pending
- 2004-06-25 JP JP2006518680A patent/JP4733028B2/en not_active Expired - Fee Related
- 2004-06-25 US US10/877,928 patent/US20050143352A1/en not_active Abandoned
- 2004-06-25 EP EP10184736A patent/EP2319829A1/en not_active Withdrawn
- 2004-06-25 EA EA200600221A patent/EA200600221A1/en unknown
- 2004-06-25 EP EP10184642A patent/EP2298322A3/en not_active Withdrawn
- 2004-06-25 EP EP04756012A patent/EP1648859B1/en active Active
- 2004-06-25 EP EP10184671A patent/EP2298323A3/en not_active Withdrawn
- 2004-06-25 CA CA002531728A patent/CA2531728A1/en not_active Abandoned
- 2004-06-25 CN CN201010143148A patent/CN101863841A/en active Pending
-
2006
- 2006-01-08 IL IL173019A patent/IL173019A0/en unknown
-
2010
- 2010-07-11 IL IL206939A patent/IL206939A0/en unknown
- 2010-10-12 JP JP2010229234A patent/JP2011063592A/en active Pending
-
2014
- 2014-05-19 US US14/281,357 patent/US9533943B2/en active Active
-
2016
- 2016-12-09 US US15/374,329 patent/US20170305840A1/en not_active Abandoned
Patent Citations (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2990331A (en) | 1956-11-23 | 1961-06-27 | Pfizer & Co C | Stable solutions of salts of tetracyclines for parenteral administration |
| US2980584A (en) | 1957-10-29 | 1961-04-18 | Pfizer & Co C | Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation |
| US3062717A (en) | 1958-12-11 | 1962-11-06 | Pfizer & Co C | Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation |
| US3165531A (en) | 1962-03-08 | 1965-01-12 | Pfizer & Co C | 13-substituted-6-deoxytetracyclines and process utilizing the same |
| US3454697A (en) | 1965-06-08 | 1969-07-08 | American Cyanamid Co | Tetracycline antibiotic compositions for oral use |
| US3304227A (en) | 1965-07-15 | 1967-02-14 | Loyal E Loveless | Antibiotic-containing animal feed |
| US3557280A (en) | 1966-05-31 | 1971-01-19 | Koninklijke Gist Spiritus | Stable solutions of oxytetracycline suitable for parenteral and peroral administration and process of preparation |
| US3674859A (en) | 1968-06-28 | 1972-07-04 | Pfizer | Aqueous doxycycline compositions |
| US3957980A (en) | 1972-10-26 | 1976-05-18 | Pfizer Inc. | Doxycycline parenteral compositions |
| US4024272A (en) | 1974-09-06 | 1977-05-17 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Tetracyclic compounds |
| US4018889A (en) | 1976-01-02 | 1977-04-19 | Pfizer Inc. | Oxytetracycline compositions |
| US4126680A (en) | 1977-04-27 | 1978-11-21 | Pfizer Inc. | Tetracycline antibiotic compositions |
| US4666897A (en) | 1983-12-29 | 1987-05-19 | Research Foundation Of State University | Inhibition of mammalian collagenolytic enzymes by tetracyclines |
| US4704383A (en) | 1983-12-29 | 1987-11-03 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
| US4925833A (en) | 1983-12-29 | 1990-05-15 | The Research Foundation Of State University Of New York | Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis |
| US4935412A (en) | 1983-12-29 | 1990-06-19 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
| USRE34656E (en) | 1983-12-29 | 1994-07-05 | The Research Foundation Of State University Of New York | Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency |
| US5308839A (en) | 1989-12-04 | 1994-05-03 | The Research Foundation Of State University Of New York | Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline |
| US5321017A (en) | 1989-12-04 | 1994-06-14 | The Research Foundation Of State University Of New York | Composition comprising fluriprofen and effectively non-antibacterial tetracycline to reduce bone loss |
| US5459135A (en) | 1989-12-04 | 1995-10-17 | The Research Foundation Of State University Of New York | Composition comprising indomethacin [non-steroidal anti-inflammatory agent] and effectively non-antibacterial tetracycline to reduce bone loss |
| US5770588A (en) | 1991-02-11 | 1998-06-23 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions of the prevention and treatment of root caries |
| US5231017A (en) | 1991-05-17 | 1993-07-27 | Solvay Enzymes, Inc. | Process for producing ethanol |
| US5258371A (en) | 1992-05-29 | 1993-11-02 | Kuraray Co., Ltd. | Method to reduce connective tissue destruction |
| US6043225A (en) | 1992-06-12 | 2000-03-28 | Board Of Regents Of The University Of Washington | Diagnosis and treatment of arterial chlamydial granuloma |
| US5532227A (en) | 1992-11-17 | 1996-07-02 | The Research Foundation Of State University Of New York | Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive glycosylation of different types of collagen and other proteins during diabetes |
| US5523297A (en) | 1993-03-02 | 1996-06-04 | The Research Foundation Of State University Of New York | Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines |
| US6043231A (en) | 1993-03-02 | 2000-03-28 | The Research Foundation Of State Univ. Of New York | Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines |
| US5668122A (en) | 1993-07-28 | 1997-09-16 | Fife; Rose S. | Method to treat cancer with tetracyclines |
| US5834450A (en) | 1994-02-17 | 1998-11-10 | Pfizer Inc. | 9- (substituted amino) -alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics |
| US5843925A (en) | 1994-12-13 | 1998-12-01 | American Cyanamid Company | Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth |
| US5834449A (en) | 1996-06-13 | 1998-11-10 | The Research Foundation Of State University Of New York | Treatment of aortic and vascular aneurysms with tetracycline compounds |
| US5827840A (en) | 1996-08-01 | 1998-10-27 | The Research Foundation Of State University Of New York | Promotion of wound healing by chemically-modified tetracyclines |
| US5919775A (en) | 1996-08-30 | 1999-07-06 | The Research Foundation Of The State University Of New York | Method for inhibiting expression of inducible nitric oxide synthase with tetracycline |
| US5789395A (en) | 1996-08-30 | 1998-08-04 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
| US5919774A (en) | 1996-12-10 | 1999-07-06 | Eli Lilly And Company | Pyrroles as sPLA2 inhibitors |
| US5837696A (en) | 1997-01-15 | 1998-11-17 | The Research Foundation Of State University Of New York | Method of inhibiting cancer growth |
| US6100248A (en) | 1997-01-15 | 2000-08-08 | Golub; Lorne M. | Method of inhibiting cancer growth |
| US5773430A (en) | 1997-03-13 | 1998-06-30 | Research Foundation Of State University Of New York | Serine proteinase inhibitory activity by hydrophobic tetracycline |
| US5929055A (en) | 1997-06-23 | 1999-07-27 | The Research Foundation Of State University Of New York | Therapeutic method for management of diabetes mellitus |
| US6277061B1 (en) | 1998-03-31 | 2001-08-21 | The Research Foundation Of State University Of New York | Method of inhibiting membrane-type matrix metalloproteinase |
| US6015804A (en) | 1998-09-11 | 2000-01-18 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds to enhance interleukin-10 production |
| US5977091A (en) | 1998-09-21 | 1999-11-02 | The Research Foundation Of State University Of New York | Method of preventing acute lung injury |
| US5998390A (en) | 1998-09-28 | 1999-12-07 | The Research Foundation Of State University Of New York | Combination of bisphosphonate and tetracycline |
| US6231894B1 (en) | 1999-10-21 | 2001-05-15 | Duke University | Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase |
| WO2003005971A2 (en) | 2001-07-13 | 2003-01-23 | Paratek Pharmaceuticals, Inc. | Tetracycline compounds having target therapeutic activities |
Non-Patent Citations (10)
| Title |
|---|
| BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, DOI: doi:10.1002/jps.2600660104 |
| CHANDLE ET AL., J. NEURØIMMUUØ/., vol. 72, 1997, pages 155 - 71 |
| GREENWALD ET AL., BONE, vol. 22, 1998, pages 33 - 38 |
| LI ET AL., MOL. CARCINOG., vol. 22, 1998, pages 84 - 89 |
| LIEDTKE ET AL., ANN. NEUROL., vol. 44, 1998, pages 35 - 46 |
| RYAN ET AL., CURR. OP. RHEUMATOL., vol. 8, 1996, pages 238 - 247 |
| STETLER-STEVENSON ET AL., ANNU. REV. CELL BIOL., vol. 9, 1993, pages 541 - 73 |
| TRYGGVASON ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 907, 1987, pages 191 - 217 |
| VAN DER BOZERT ET AL., CANCER RES., vol. 48, 1988, pages 6686 - 6690 |
| WAITZ, J.A.: "National Commission for Clinical Laboratory Standards, Document M7-A2", vol. 10, 1990, VILLANOVA, pages: 13 - 20 |
Cited By (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2277504A1 (en) * | 2002-10-24 | 2011-01-26 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for the treatment of malaria |
| EP2408192A2 (en) | 2004-04-16 | 2012-01-18 | James A. Aman | Multiple view compositing and object tracking system |
| US7858601B2 (en) | 2004-10-25 | 2010-12-28 | Paratek Pharmaceuticals, Inc. | 4-substituted tetracyclines and methods of use thereof |
| US8466132B2 (en) | 2004-10-25 | 2013-06-18 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| EP2284152A3 (en) * | 2004-10-25 | 2011-10-05 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| EP2269978A3 (en) * | 2004-10-25 | 2011-09-21 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| EP2305637A3 (en) * | 2004-10-25 | 2011-09-21 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| EP2033950A1 (en) * | 2004-10-25 | 2009-03-11 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| EP2269985A3 (en) * | 2004-10-25 | 2011-09-21 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| EP2284150A3 (en) * | 2004-10-25 | 2011-09-21 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| EP2284151A3 (en) * | 2004-10-25 | 2011-09-21 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| US7534766B2 (en) | 2004-11-05 | 2009-05-19 | Wyeth | Glucuronide metabolites and epimers thereof of tigecycline |
| JP2009502809A (en) * | 2005-07-21 | 2009-01-29 | パラテック ファーマシューティカルズ インコーポレイテッド | 10-Substituted Tetracycline and Method of Use |
| WO2007014154A3 (en) * | 2005-07-21 | 2007-08-23 | Paratek Pharm Innc | 10-substituted tetracyclines and methods of use thereof |
| WO2007014154A2 (en) * | 2005-07-21 | 2007-02-01 | Paratek Pharmaceuticals, Inc. | 10-substituted tetracyclines and methods of use thereof |
| US9078811B2 (en) | 2006-01-24 | 2015-07-14 | Paratek Pharmaceuticals, Inc. | Methods of increasing oral bioavailability of tetracyclines |
| JP2009524675A (en) * | 2006-01-24 | 2009-07-02 | パラテック ファーマシューティカルズ インコーポレイテッド | Methods to increase the oral bioavailability of tetracycline |
| US8440646B1 (en) | 2006-10-11 | 2013-05-14 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of Bacillus anthracis infections |
| EP3812372A3 (en) * | 2006-12-21 | 2021-06-30 | Paratek Pharmaceuticals, Inc. | 7-heterocyclyl substituted sancycline derivatives for treating bacterial, viral and parasitic infections (e.g. malaria) or inflammatory diseases |
| AU2007338681B2 (en) * | 2006-12-21 | 2013-09-26 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
| US9481639B2 (en) | 2006-12-21 | 2016-11-01 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
| WO2008079363A3 (en) * | 2006-12-21 | 2008-10-02 | Paratek Pharm Innc | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
| WO2008079363A2 (en) * | 2006-12-21 | 2008-07-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
| EP3045449A1 (en) * | 2006-12-21 | 2016-07-20 | Paratek Pharmaceuticals, Inc. | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections |
| US8318706B2 (en) | 2006-12-21 | 2012-11-27 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| EP3488853A1 (en) * | 2006-12-21 | 2019-05-29 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
| JP2015205939A (en) * | 2006-12-21 | 2015-11-19 | パラテック ファーマシューティカルズ インコーポレイテッド | Tetracycline derivative for treatment of bacteria infection, virus infection and parasite infection |
| JP2011093914A (en) * | 2006-12-21 | 2011-05-12 | Paratek Pharmaceuticals Inc | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections |
| JP2018039846A (en) * | 2006-12-21 | 2018-03-15 | パラテック ファーマシューティカルズ インコーポレイテッド | Tetracycline derivatives for treatment of bacterial, viral and parasitic infections |
| US8513223B2 (en) | 2006-12-21 | 2013-08-20 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
| US9434680B2 (en) | 2007-04-27 | 2016-09-06 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing and purifying aminoalkyl tetracycline compounds |
| AU2010200845B2 (en) * | 2007-07-06 | 2013-01-17 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing substituted tetracycline compounds |
| JP2010532759A (en) * | 2007-07-06 | 2010-10-14 | パラテック ファーマシューティカルズ インコーポレイテッド | Method for the synthesis of substituted tetracycline compounds |
| WO2009009042A1 (en) * | 2007-07-06 | 2009-01-15 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing substituted tetracycline compounds |
| CN101784517A (en) * | 2007-07-06 | 2010-07-21 | 帕拉特克药品公司 | The method of the synthetic tetracycline compound that replaces |
| EP2192111A3 (en) * | 2007-07-06 | 2010-10-06 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing substituted tetracycline compounds |
| US9522872B2 (en) | 2007-07-06 | 2016-12-20 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing substituted tetracycline compounds |
| AU2008275701B2 (en) * | 2007-07-06 | 2013-04-04 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing substituted tetracycline compounds |
| JP2011020996A (en) * | 2007-07-06 | 2011-02-03 | Paratek Pharmaceuticals Inc | Method for synthesizing substituted tetracycline compound |
| US8487093B2 (en) | 2008-01-18 | 2013-07-16 | Merck Sharp & Dohme Corp. | β-lactamase inhibitors |
| US8796245B2 (en) | 2008-08-08 | 2014-08-05 | Tetraphase Pharmaceuticals, Inc. | C7-fluoro substituted tetracycline compounds |
| US8906887B2 (en) | 2008-08-08 | 2014-12-09 | Tetraphase Pharmaceuticals, Inc. | C7-fluoro substituted tetracycline compounds |
| US10072007B2 (en) | 2009-05-08 | 2018-09-11 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| US9315451B2 (en) | 2009-05-08 | 2016-04-19 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| EP2427425B1 (en) * | 2009-05-08 | 2017-03-08 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| US9624166B2 (en) | 2009-08-28 | 2017-04-18 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| WO2012068106A2 (en) | 2010-11-15 | 2012-05-24 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| EP2738156A4 (en) * | 2011-07-26 | 2015-01-07 | Kbp Biosciences Co Ltd | 9-aminomethyl substituted tetracycline compound |
| US9365499B2 (en) | 2011-07-26 | 2016-06-14 | Kbp Biosciences Co., Ltd. | 9-aminomethyl substituted tetracycline compounds |
| EP2738156A1 (en) * | 2011-07-26 | 2014-06-04 | KBP Biosciences Co., Ltd. | 9-aminomethyl substituted tetracycline compound |
| US9573895B2 (en) | 2012-08-31 | 2017-02-21 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| US10315992B2 (en) | 2012-08-31 | 2019-06-11 | Tetraphase Pharmaceuticals, Inc. | Tetracyline compounds |
| US10913712B2 (en) | 2012-08-31 | 2021-02-09 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| US10961190B2 (en) | 2016-10-19 | 2021-03-30 | Tetraphase Pharmaceuticals, Inc. | Crystalline forms of eravacycline |
| US11578044B2 (en) | 2016-10-19 | 2023-02-14 | Tetraphase Pharmaceuticals, Inc. | Crystalline forms of eravacycline |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2298322A2 (en) | 2011-03-23 |
| EP2319828A2 (en) | 2011-05-11 |
| EA201100956A1 (en) | 2012-01-30 |
| AU2004259659A1 (en) | 2005-02-03 |
| EP1648859A2 (en) | 2006-04-26 |
| US20050143352A1 (en) | 2005-06-30 |
| JP4733028B2 (en) | 2011-07-27 |
| CN101863841A (en) | 2010-10-20 |
| WO2005009943A3 (en) | 2005-06-16 |
| US20150045329A1 (en) | 2015-02-12 |
| US9533943B2 (en) | 2017-01-03 |
| EA201001081A1 (en) | 2011-02-28 |
| EP2295404A3 (en) | 2011-05-11 |
| AU2004259659B2 (en) | 2011-11-03 |
| EA200600221A1 (en) | 2006-06-30 |
| JP2007521290A (en) | 2007-08-02 |
| CN1845897A (en) | 2006-10-11 |
| CN101786991A (en) | 2010-07-28 |
| US20170305840A1 (en) | 2017-10-26 |
| KR101228706B1 (en) | 2013-02-01 |
| EP2298323A3 (en) | 2011-05-11 |
| IL173019A0 (en) | 2006-06-11 |
| JP2011063592A (en) | 2011-03-31 |
| EP2298322A3 (en) | 2011-05-11 |
| EP1648859B1 (en) | 2013-02-27 |
| EP2295404A2 (en) | 2011-03-16 |
| KR20060035734A (en) | 2006-04-26 |
| EP2319829A1 (en) | 2011-05-11 |
| EP2298323A2 (en) | 2011-03-23 |
| IL206939A0 (en) | 2010-12-30 |
| EP2319828A3 (en) | 2011-07-06 |
| CA2531728A1 (en) | 2005-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9533943B2 (en) | Substituted tetracycline compounds | |
| EP1805134B1 (en) | 4-aminotetracyclines and methods of use thereof | |
| US7820641B2 (en) | Substituted tetracycline compounds | |
| US8481513B2 (en) | 3, 10, and 12a substituted tetracycline compounds | |
| EP2316450A1 (en) | Amino-methyl substituted tetracycline compounds | |
| EP2332904A2 (en) | Derivatives of tetracycline compounds | |
| CA2744317A1 (en) | Substituted tetracycline compounds | |
| AU2012200575A1 (en) | Substituted tetracycline compounds | |
| AU2012216640A1 (en) | 4-aminotetracyclines and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200480025635.1 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase |
Ref document number: 2531728 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020067000487 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006518680 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004259659 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004756012 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 490/CHENP/2006 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 200600221 Country of ref document: EA |
|
| ENP | Entry into the national phase |
Ref document number: 2004259659 Country of ref document: AU Date of ref document: 20040625 Kind code of ref document: A |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004756012 Country of ref document: EP Ref document number: 1020067000487 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 206939 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 223858 Country of ref document: IL |